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CHOLESTEROL 
Cholesterol is a lipid that plays several roles. This steroid, a mostly hydrophobic molecule with a 
3β-hydroxyl group, is an essential structural element of the cell membrane. Its amphipathic 
character allows interaction of the cholesterol polar hydroxyl group with the polar head of the 
phospholipids in the cell membrane, while the hydrophobic steroid ring is oriented parallel to, and 
buried in, the hydrocarbon chains of the phospholipid bilayer (Bastiaanse et al 1997). Thanks to 
these special physical properties, cholesterol reduces the fluidity (Myant 1981) and modulates the 
permeability, the formation of lipid raft and the functions of the proteins of the membranes (Levy 
et al 2007). In addition to its structural role, cholesterol is a precursor for the synthesis of steroid 
hormones (in surrenal glands, ovaries and testicles), bile acids (in liver) and vitamin D (in 
skin)(Ikonen et al 2008).                                      
The presence of cholesterol is essential for life, but any excess entails severe clinical implications: 
it is thus obvious that adequate regulation of cholesterol homeostasis is necessary. Cholesterol 
concentration in human blood is in the range 100-300 mg/dl (Charlton-Menys et al 2008).  
Cholesterol homeostasis is maintained through a balance between de novo synthesis, intestinal 
absorption and fecal excretion (Wang et al 2012). The typical human diet contains 200-500 mg of 
cholesterol/day (Borgstrom et al 1960). Between 30 and 60% of intestinal cholesterol is absorbed 
through specific transporters. In addition, the steroid lipid enters the intestinal tract from other 
two sources: bile (800-1200 mg day) and secretion by intestinal mucosa (300 mg day). Cholesterol 
can also be produced de novo by organs as liver, intestinal wall and central nervous system. A 
fraction of cholesterol is continuously lost from the organism: 550 mg/day as fecal bile loss and as 
desquamated 250 mg/day , as unabsorbed bile salts and 100 mg/day in sebum (Levy et al 2007).  
Synthesis of cholesterol 
The cholesterol biosynthetic pathway (Figure 1) is a complex metabolic process that involves more 
than 30 reactions utilizing over 15 enzymes from many different subcellular compartments. 
Cholesterol is synthesized from its precursor unit acetyl coenzyme A and at least 21 steps are 
required to carry out the overall process. The synthesis starts with the formation of the six-carbon 
intermediate 3-hydroxy-3methylglutaryl-coenzyme A (HMG-CoA) from one molecule of acetyl-CoA 
and one of acetoacetyl-CoA, in a reaction catalyzed by the enzyme 3-hydroxy-3methylgluraryl-
coenzyme A synthase (HMGCS). The enzyme 3-hydroxy-3methylgluraryl-coenzyme A reductase 
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(HMGCR), is bound to the membranes of the endoplasmatic reticulum and catalyzes the 
conversion of  HMG-CoA to mevalonate. The conversion of HMG-CoA to melanovate represents 
the rate limiting reaction of cholesterol synthesis. Through several condensation reactions, 
mevalonate is transformed into a long-chain hydrocarbon, squalene which is cyclized and 
transformed into cholesterol (Grundy et al 1978)(Alphonse et al 2016).  
 
 
 
Figure 1. Pathway of cholesterol synthesis. 
 
Absorption of cholesterol 
The absorption of cholesterol (Figure 2) from the intestine is an important aspect of cholesterol 
metabolism. The entire small intestine can absorb this lipid from the lumen, but the major sites of 
absorption are in its upper part (duodenum and proximal jejunum). In addition to a simple passive 
diffusion through the membranes, this process involves specific proteins which are able to 
transport the steroid across the intestinal wall.                                                                                                                                     
Niemann-Pick C1 Like 1 (NPC1L1) plays a pivotal role in cholesterol absorption. This protein, 
located in the proximal intestine (jejunum), actively facilitates the uptake of cholesterol by 
promoting the passage of sterols across the brush border membrane of the intestinal cells (Wang  
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et al 2007). NPC1L1 shows several of the predicted features of a plasma membrane–expressed 
transporter including a secretion signal, 13 putative trans-membrane domains and several 
potential N-linked glycosylation sites located within the extracellular loops of the protein. 
Moreover, this transporter contains a sterol-sensing domain, which is present in other key 
regulators of cholesterol homeostasis including HMGCR, SREBP cleavage-activating protein (SCAP), 
PATCHED, and Niemann-Pick C1 (NPC1). Studies performed on mice knock-out in this protein 
revealed an 80% decrease in intestinal cholesterol absorption. In addition, when NPC1L1 null-mice 
were treated with ezetimibe, a specific and potent inhibitor of intestinal cholesterol absorption in 
rodents and in humans, the treatment had no effects. Therefore, NPC1L1 represents the molecular 
target of ezetimibe (Altmann et al 2004). 
In the proximal small intestine, NPC1L1 co-localizes with two ATP-binding cassette (ABC) 
transporters, ABCG5 and ABCG8, membrane proteins that transport a variety of substrates across 
the extra- and intra-cellular membranes. These transporters promote active efflux of un-esterified 
cholesterol from enterocytes into the intestinal lumen for excretion (Duan et al 2004). Intracellular 
cholesterol that is not effluxed by ABCG5/G8, travels to the endoplasmatic reticulum (ER), where it 
is esterified by acyl CoA:cholesterol acyltransferase 2 (ACAT2). The esterified cholesterol is then 
incorporated into chylomicrons (CMs),  together with triglycerides (TG), phospholipids (PH) and 
apolipoprotein (apo) B48 and finally it is delivered to the thoracic duct (Lee et al 2000).  
Scavenger receptor type BI (SR-BI) is an additional element of intestinal cholesterol absorption. SR-
BI is an 82 kDa membrane protein mostly expressed in liver and steroidogenic tissues. It is also 
expressed in enterocyte brush border membranes mainly at the top of intestinal villosities and in 
the proximal part of intestine, where most cholesterol absorption occurs. However, the relevance 
of SR-BI in intestinal cholesterol absorption is not beyond question since the disruption of SR-BI 
gene in mice does not affect cholesterol absorption. The effect is thus complex with the overall 
process depending on the combined actions of transporter proteins involved in both uptake and 
efflux of cholesterol, which could compensate for the lack of SR-BI from the intestine (Hauser et al 
1998). 
Among the transporters facing the intestinal lumen, CD 36 seems involved in cholesterol 
absorption. Originally identified as a receptor for oxidized low-density lipoproteins, it is a 75–88 
kDa, 472 aminoacid-long, glycosilated transmembrane protein, which actually shows a wide ligand 
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specificity for different lipoproteins, glycosylated proteins, thrombospondin-1 and other 
molecules. CD 36 is ubiquitously expressed and major sites of its synthesis are heart, skeletal 
muscle, adipose tissue, intestine, and the capillary endothelium (Abumrad et al 2012). 
In addition, enterocytic cholesterol can be transferred to apolipoprotein A1 (apoA-I), the mainly 
protein component of high density lipoprotein (HDL), via ATP-binging cassette transport A1 
(ABCA1) (Brunham et al 2006). 
 
 
 
 
 
Figure 2. Pathway of cholesterol absorption. 
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Regulation of cholesterol homeostasis 
Proper regulation of cholesterol homeostasis in the body is essential for human health. HMGCR 
catalyzes the conversion of HMGCoA to mevalonate, the precursor of isoprenoid groups that are 
incorporated into many end-products including cholesterol, ubiquinone, heme, dolichol and the 
farnesyl and geranylgeranyl groups that can become attached to many cellular proteins (Goldstein  
et al 1990). Thus, it is very important to regulate mevalonate synthesis to assure constant 
production of compounds that contain isoprenoid moieties. On the other hand, the synthesis of 
cholesterol is highly regulated also in order to prevent over accumulation and abnormal 
deposition in the bodyof toxic products, such as cholesterol itself (Kellner-Weibel et al 1998). 
Intracellular levels of cholesterol are tightly regulated by a system of feedback that operate at 
both transcriptional and post-trascriptional level (Brown et al 1997), resulting in the modulation of 
the expression of key proteins that control cholesterol homeostasis (Ye et al 2011).  
The sterol regulatory element binding proteins (SREBPs, in particular of type 2) play an important 
role in this process. When cellular cholesterol is high, SREBP2 is located in the endoplasmatic 
reticulum (ER) in a complex with SREBP2 cleavage-activating protein (SCAP). Conversely, when 
cells are depleted of sterols, SCAP escorts SREBP2 from the ER to the Golgi apparatus, where it is 
cleaved to release cleavage product from the membrane. This SREBP2 proteolytic fragment can 
then enter the nucleus and activate the transcription of multiple genes regulating cholesterol 
synthesis by binding to a sterol response element (SRE) in their enhancer/promoter regions 
(Horton et al 2002). SREBPs can increase the up-take of cholesterol through the activation of 
transcription of the LDL receptor (LDLR)(Brown et al 1997). Discovered in 1974, LDLR is a cell 
membrane glycoprotein involved in the binding and internalizing of circulating cholesterol 
containing lipoprotein particles. These endocytic receptors are ubiquitously expressed and are a 
key element for maintaining cholesterol homeostasis in mammals. 
Liver X receptors (LXRs), a family of transcription factors that were first identified as orphan 
members of the nuclear receptor superfamily,  play a central role in the regulation of lipid 
metabolism. Two isoforms exist: LRXα e LRXβ. The first is expressed in spleen, liver, adipose tissue, 
intestine, kidney and lung, while the second is ubiquitous. The first identified target gene directly 
regulated by LXRs was a cytochrome P450 family member, CYP7A1, which is the rate-limiting 
enzyme in hepatic bile synthesis. Several studies have shown that LRXs regulate the expression of 
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different genes involved in cholesterol transport and metabolism. LRXs represent the key sensors 
of intracellular sterol levels that activate adaptive mechanism in response to cholesterol overload, 
including stimulation of reverse cholesterol transport and biliary cholesterol excretion, inhibition 
of intestinal absorption of dietary cholesterol and suppression de novo of cholesterol synthesis 
(Nakamura et al 2004). Experiments performed on mice lacking  LXR α and fed a high fat diet, 
resulted in massive hepatic accumulation of cholesterol esters, hepatomegaly and 
hypercholesterolemia. This effect is due to the absence of LXRα that cannot induce CYP7A1. The 
only presence of LXRβ in the liver cannot compensate the absence of LXRα in regulating Cyp7a1 
(Peet et al 1998). In addition, LXRα is essential for the up-regulation of the ABCG5 and ABCG8 
genes in response to high dietary cholesterol.  
Also microRNAs  (miRNAs), members of a class of non-coding RNAs, are considered novel post-
transcriptional regulators of cholesterol homeostasis (Meaney et al 2014). In particular, microRNA-
33 (miR-33) can down regulate the expression of ABCA1 and ABCG1, resulting in the control of 
cholesterol efflux and HDL biogenesis. Other miRNAs, such as miR-122, miR-370, miR-378-378, 
miR-125a, miR-27 and miR355, are involved in cholesterol homeostasis (Goedeke et al 2012). 
 
LIPOPROTEINS 
As completely insoluble in water, cholesterol cannot circulate freely in plasma but must be 
transported by complex carriers: the lipoproteins (Grundy et al 1978). Lipoproteins are 
macromolecules containing an hydrophobic central core of neutral lipids such as cholesteryl esters 
(CE) and triglycerides and a surface rich in proteins (apolipoproteins), and in polar lipids, mainly 
phospholipids and unsterified (free) cholesterol (FC)(Figure 3)(Rader, D. J 2008). 
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Figure 3. Representation of lipoprotein structure. 
 
Plasma lipoproteins are characterized by a different ratio between free cholesterol (FC), esterified 
cholesterol (CE), PL, TG and by the presence of different apolipoproteins. They are classified into 
five major classes: chylomicrons, very low-density lipoprotein (VLDLs), intermediate-density 
lipoprotein (IDLs), low-density lipoprotein (LDLs) and high-density lipoprotein (HDLs)(Table 1) 
(Hoofnagle  et al 2009). 
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Table 1. Classification and properties of plasma lipoproteins. 
Chylomicrons 
Chylomicrons are the largest lipoproteins (up to 100 mm in diameter) with the lowest protein-to-
lipid ratio (being about 90 percent lipid) and therefore they are the least dense (less than 0.95 
g/ml). CMs are triglyceride-rich particles with a central lipid core and an outer layer of 
phospholipids, free cholesterol and apolipoproteins (Hamilton R.L. 1972). ApoB48 represents the 
main apolipoprotein in this particles, but other apolipoproteins are on their surface, including 
apoAI, apoAIV, and apoCs (Hussain et al 1996).                                                                                                                                                               
CMs are formed in enterocytes in response to fat ingestion; they transport dietary triglycerides to 
peripheral tissues and cholesterol to the liver (Julve et al 2016). Triglycerides, which represent the 
principal fat in diet, are absorbed from mixed micelles formed in the intestinal lumen by fatty acids 
and monoglycerides after the hydrolysis of the ester bonds catalyzed by intestinal and pancreatic 
lipases. In the endoplasmatic reticulum of enterocytes, triglycerides are resynthesized and 
complexed with ApoB48, in a process involving Microsomal Triglyceride Transfer Protein (MTP), to 
form primordial chylomicrons particles (pre-chylomicron)(Olofsson et al 2000). Then, the pre-
chylomicrons are included in a unique transport vesicle, the pre-chylomicron transport vesicle 
(PCTV), which are budded off the endoplasmic reticulum (ER) membrane and transported to the 
Golgi apparatus (Kumar et al 1999). Once into the Golgi compartment chylomicrons undergo 
further modifications such as addition of apoA-I and glycosylation of apoB48.  They are then fused 
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into another transport vesicle and are transferred to the basolateral membrane for secretion in 
the general circulation (Hussain et al 2000).  
Once chylomicrons are secreted via the intestinal lymphatic system they enter the blood 
circulation, bind some apoE and ApoC and eventually come into contact with lipoprotein lipase 
(LPL), which is located on the luminal surface of the vascular endothelium of tissues such as 
skeletal muscle and adipose tissue. This enzymes, activated by apoC-II,  hydrolyses the 
triglycerides of CM, which as a result become smaller, cholesterol-rich chylomicron remnants. The 
released fatty acids and monoglycerides are either taken up locally by cells, in which they are used 
for energy or stored as triglycerides in adipocytes (Cooper et al 1997).  Remnants are cleared from 
the circulation by the liver in a process that involves apoE, present on the chylomicron remnants, 
apoE binds to the LDL receptor and to other hepatic receptors such as  LDL receptor like protein 
(LRP) leading to the up take of the entire particle by the hepatocytes (Mjos et al 1975). Remnants 
contain apoB48 as their nascent precursors, but have different composition and structure from 
CMs. They are depleted in tryglicerides, phospholipids and apoCs and are enriched in cholesteryl 
esters (CE), which they acquire from HDL through the action of cholesteryl ester transfer protein 
(CETP).  
Very Low-Density Lipoproteins 
Very low-density lipoproteins (VLDLs) are characterized by a density between 0,95 and 1006 g/ml 
and by a diameter of 30-80 nm. As CMs, VLDLs are triglyceride-rich lipoproteins containing small 
amounts of cholesterol and phospholipids. They represent the major vehicle in the plasma which 
transfer triglycerides synthetized in the liver to peripheral tissues. Thus, CMs transport dietary 
lipids, whereas VLDLs are involved in endogenous lipid pathway. VLDLs are produced by the liver, 
where triglycerides and cholesterol esters are transferred to ER with Apo B-100, a large 
hydrophobic protein which represents the main structural component of these lipoproteins. As for 
CMs, the assembly of triglycerides and the apoB-100 to form VLDLs is mediated by MTP. After 
their biogenesis, in the ER, VLDLs are transferred by a specialized transport vesicle, the VLDL 
transport vesicle, into the Golgi apparatus, for their eventul secretion from the hepatocytes 
(Tiwari et al 2012). The availability of triglycerides is the main determinant of the rate of VLDLs 
synthesis. MTP is essential for the association between lipid and Apo B-100. Mutations of MTP 
result in the failure block of VLDLs production and in a marked decrease in plasma levels of 
11 
 
triglycerides and cholesterol. Betalipoproteinemia is caused by molecular defect in this process. If 
either the supply of triglycerides is limited or MTP is altered, the newly synthesized Apo B is 
rapidly degraded. When VLDL particles are secreted into the circulatory system, the triglycerides 
are hydrolyzed by LPL, fatty acids are released and the particles acquire apoE and apoC from HDL. 
This change leads to the formation of IDLs (Shelness et al 2001). 
Intermediate density lipoproteins  
IDL particles have an intermediate density of 1,006-1,019 g/ml and a diameter of 25-30 nm. These 
lipoproteins are relatively enriched in cholesterol esters, contain apoB-100 and acquire Apo E from 
HDL particles. ILDs are present in blood at low concentration and are characterized by a short half-
life. As the remnants, IDL particles are removed from the circulation by the liver via the LDL 
receptors. While remnants are rapidly removed from the blood by the liver, only a fraction of IDL 
particles are cleared. The triglycerides remaining in the IDL are hydrolyzed by the hepatic lipase. 
This event leads to an additional decrease in triglyceride content and the exchangeable 
apolipoproteins are transferred from the IDL particles to other lipoproteins to form LDL (Tatami et 
al 1981). 
Low density lipoprotein 
LDLs are lipoproteins with density of 1,009-1063 mg/dl and whit size of 18-28 nm. These particles 
are the major carriers of circulating cholesterol and represent the final stage of catabolism of 
VLDL, through the progressive depletion in triglycerides content (Figure 4). LDLs are formed by a 
core of cholesterol esters surrounded by a phospholipid monolayer and apoB-100, that in addition 
to its structural function, it behaves as a ligand (Driscoll et al 1986). The main function of LDL 
particles is to transport and deliver cholesterol to peripheral tissues. The LDL lipoproteins are 
removed via whole-particle endocytosis mediated by LDLR (Goldstein et al 1985). These receptors 
are expressed mainly on hepatocytes surface. The receptor-LDL complex, is internalized as a part 
of a vesicle; the LDL particles are then released inside a lysosome, a cellular organelle that 
contains acid hydrolases that could easily digest all the components of LDL and free cholesterol. 
LDL lipoproteins concentration in plasma is determined by the rate of LDL production and 
clearance. Both processes are regulated by the number of LDLR in the liver. An increase in hepatic 
LDLR leads to increase LDL clearance resulting in reduction of plasma LDL levels. On the other 
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hand, a decrease in hepatic LDLR slows LDL clearance leading to an increase in plasma LDL levels. 
The expression of these receptors is subjected to feedback regulation by the cholesterol content 
of the cells. When the intracellular cholesterol increases, the synthesis of LDLR is reduced, so the 
uptake of LDL by the cell is reduced. Conversely, when cell cholesterol levels decrease, SREBPs, 
which are transcription factors that modulate the expression of LDLR, together with other gene 
products involved in cholesterol metabolism, are transported to the nucleus, where they stimulate 
the transcription of their targets. As previously mentioned, this include HMG-CoA reductase, the 
regulatory enzyme of cholesterol synthesis  (Goldstein et al 2009). 
 
 
 
Figure 4. Metabolism of VLDL and LDL lipoproteins. 
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High density lipoproteins 
 
High-density lipoproteins structure 
HDLs are lipoproteins characterized by a density of 1.063-1.210 g/ml and by a diameter of 5-15 
nm. HDLs are dynamic particles and represent an heterogeneous family of lipoproteins differing in 
size, shape, charge and density. HDL are constituted by 50% protein and 50% lipid. Most part of 
plasma HDLs are characterized by globular shape, with a core of neutral lipids (triglycerides and 
cholesteryl esters) stabilized by a surface of polar lipids (phospholipids and unsterified cholesterol) 
and apolipoproteins (Gu et al 2010). HDL particles are heterogeneous in their proteome. The 
protein component of HDL is formed principally by apoA-I (70%) and apoA-II (20%). Recent 
proteomic analysis have identified more than 60 proteins among them other apoliporoteins such 
as apoA-IV, apoCs, apoE, as well as many enzymes including lecithin:cholesterol acyltransferase 
(LCAT), cholesteryl ester transfer protein (CEPT), phospholipid transfer protein (PLTP) and 
paraoxonase (PON) (Shah et al 2013).  
HDL can be classify on the basis of density, charge, shape and size. Based on density, it is possible 
to identify two different HDL subclasses, called HDL2 (1.063 to 1.12 g/ml) and HDL3 (1.12 to 1.21 
g/ml). As for charge, it was discovered that, upon agarose gel electrophoresis, HDL split into α- and 
pre-β-migrating particles. By combining charge and size these two subclasses can be categorized 
into 12 distinct apoA-I-containing HDL particles, referred to as pre-β (pre-β1 and pre- β 2), α (α 1, 
α 2 and α 3) and pre- α (pre- α 1, pre- α 2 and pre- α 3) on the basis of whether their mobility is 
slower or faster, respectively, than that of albumin and of whether their size is larger or smaller. 
Finally five different subclasses were identified on the basis of particle size: HDL3c, 7.2-7.8 nm; 
HDL3b, 7.8-8.2 nm; HDL3a, 8.2-8.8nm; HDL2a, 8.8.-9.7 nm; HDL2b, 9.7-12.0 nm (Nichols et al 
1986). 
 
High-density lipoprotein metabolism 
HDL lipoproteins are synthetized by liver and intestine and part of them delivers from triglyceride- 
rich lipoproteins. The newly-made HDLs, so called “nascent HDLs”, have a discoidal shape. These 
HDL particles are essentially composed of PL and apoA-I (Duong PT 2008). Once in the circulatory 
system they participate in reverse cholesterol transport, a process that removes the excess of 
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cholesterol from peripheral tissues and deliveres it to liver (Miller 1990). Nascent HDLs represent a 
substrate for lethicin:cholesterol acyltransferase (LCAT), a 63-KDa glycoprotein primarily 
synthesized in the liver and a lower extent in other tissues, such as brain and testes, that esterifies 
the free cholesterol of HDLs into cholesteryl ester. The hydrophobic nature of CE allows its to 
transfer into core of HDL particles, which results in a spherical shape for cholesterol-laden HDLs. 
Only a trace amount of CE remains in the core of HDL. CETP, an enzyme present in human, but not 
in mice, mediates the equimolar transfer of the majority CE from HDLs for TG from LDLs, VLDLs or 
chylomicrons. Triglycerides on HDL lipoproteins are catabolized  by hepatic lipase leading to the 
formation of small HDL particles. The cholesterol on HDLs is above all delivered to the liver, 
through a transport mediated by SR-B1. After this step, the cholesterol-depleted HDLs become 
smaller in size and go back to circulatory system. 
 
High-density lipoprotein functions 
Several studies have showed the existence of a strong correlation between plasma high-density 
lipoprotein cholesterol levels and the incidence of vascular disease (Gordon et al 1977). The 
athero-protection mediated by HDL is exerted through reverse cholesterol transport (RTC), as well 
as through their anti-oxidant, anti-apoptotic, anti-inflammatory and anti-thrombotic properties.  
Reverse Cholesterol Transport 
The anti-atherogenic action of HDLs is mainly due to the reverse cholesterol transport (RCT) 
(Figure 5), a pathway that removed cholesterol from peripheral cells, including macrophages 
within the arterial wall, and delivers it to the liver for excretion through bile and feces. With this 
process, HDL particles decrease cholesterol accumulation in vessel walls, preventing 
atherosclerosis development (Franceschini et al 1991). RCT is a complex process in which the HDLs 
and their mainly protein component ApoA-I play a key role.  
Cholesterol efflux from cells of peripheral tissues represents the first and limiting step of RCT. 
Several in vitro studies have shown the ability of HDL particles  to promote the removal of 
cholesterol from cell membranes (von Eckardstein et al 1996). ApoA-I plays a key role in this 
process, through its interactions with the surface of plasma membranes and with the receptors 
involved in efflux. Cholesterol can be removed by HDL via a number of mechanisms. The first one 
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is aqueous diffusion, the passive diffusion of cholesterol from plasma membranes to HDLs, which 
occurs according to the direction of cholesterol gradient (Rothblat et al 1992). The second is 
receptor-mediated process. Different membrane proteins have been identified as players in this 
pathway. Among them, ATP-binding cassette transporter A1 (ABCA1) is involved in an 
unidirectional (cell to acceptor) and ATP-dependent transport. Lipid-free/lipid-poor 
apolipoproteins, in particular apoA-I, represent the principal cholesterol ABCA1 acceptors (Jessup 
et al 2006). The interaction between ABCA1 and apoA-I promotes cholesterol and phospholipid 
efflux from ABCA1 to apoA-I, with generation of small, discoidal pre-β-HDL. These particles can 
remove further cholesterol from cells through the same pathway (Favari et al 2009). Mutations in 
the ABCA1 gene, results in Tangier Disease, an autosomal recessive disorders characterized by an 
almost totally absence of HDL-cholesterol, by reduced LDL-cholesterol, by high levels of 
triglycerides and by cholesterol accumulation in several tissues such as liver, spleen and intestine. 
The patients affected by Tangier Disease are unable to produce discoidal HDL hence cannot 
promote peripheral cholesterol removal (Brooks-Wilson A 1999). A second transporter, ATP-
binding cassette transport G1 (ABCG1), is involved in cholesterol homeostasis. Also this receptor is 
characterized by unidirectional ATP-dependent transport. ABCG1 is an essential cholesterol 
acceptor for all plasma HDL subclasses, including mature α-HDL particles and discoidal pre-β-HDL . 
The pivotal role in HDL-mediated cholesterol efflux by both ABCA1 and ABCG1 is suggested by 
their high expression in macrophages, in particular after cholesterol loading.  SR-BI mediates 
bidirectional flux of unesterified cholesterol between cells and mature HDLs, but not small pre-β -
HDL(Jessup et al 2006). SR-BI is active not only in the first step of RCT, but also in the last phase 
during the up-take of mature HDLs by liver.  
The free cholesterol accumulated in pre-β-HDLs is solubilized in the phospholipid layer at the 
surface of HDL particles to be rapidly esterified by LCAT with the formation of cholesteryl esters. 
Being an activator of LCAT, apoA-I represents a key of esterification. The hydrophobic CE is then 
moved to the core of HDLs whereas free cholesterol is removed from the surface of the HDL, 
leading to an expansion of these lipoproteins to become spherical HDLs. 
Once CEs are accumulated in their core HDLs transport CE to peripheral cells and tissues, and back 
to the liver through different mechanisms. CETP can catalyzed the transfer of cholesteryl ester, 
generated by LCAT, in HDLs to apoB containing lipoproteins laden with triglycerides. The resulting 
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lipoproteins characterized by a low density are then catabolized by the liver. The lipid-free and 
lipid-poor apoA-I, which dissociates from HDL particles as a consequence of CETP-mediated 
transfer of core lipids to other lipoproteins, may be cleared from the circulation by the endocytic 
receptors, megalin and cubulin, which are expressed in the kidney (von Eckardstein et al 2001). 
Cholesteryl esters are also selectively removed from HDLs when they bind to SR-BI on the surface 
of hepatocytes (Glass et al 1983). In vitro studies have demonstrated that the hepatic lipase 
facilitaties this process through a mechanism that involves the binding of HDLs to the cell surface. 
(Lambert et al 1999). Furthermore, HDLs can accumulate apoE and are eventually taken up by  
liver though the LDL receptors. 
 
 
 
 
 
   
 
 
 
 
 
Figure 5. Pathway of reverse cholesterol transport 
 
Anti-inflammatory function 
Among the anti-atherogenic functions of HDLs in addition to RCT, one of the best studied is the 
anti-inflammatory properties. HDLs have been known for 20 years to be anti-inflammatory 
particles (Cockerill GW 1995). Atherosclerosis is a chronic inflammatory disease characterized by 
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accumulation of oxidized LDLs (LDL-ox) and by the presence in the vessel walls of inflammatory 
cells such as macrophages, differentiated from monocytes, and T lymphocytes and by plasma 
several inflammatory markers (Libby 2002). LDL-ox stimulate endothelial cells to express 
monocyte chemotactic protein-1 (MCP-1). The production of this factor promotes the migration of 
leukocytes into the arterial vessel. HDL particles are able to suppress the expression of MCP-1, 
decreasing monocytes transmigration (Navab M 1991). When monocytes entry the arteries, LDLox 
induce their differentiation into macrophage, the most important inflammatory cell of 
atherosclerosis. Through cytokines production, these cells are able to activate endothelial cells, in 
which they induce the expression of cell adhesion molecules including vascular cell adhesion 
molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-selectin (Baker PW 1999). 
The induction of these adhesion proteins is mediated by NF-B transcriptional activation. HDLs can 
exert the anti-inflammatory properties inhibiting endothelial cell and monocytes activation 
through the suppression of NF-kB activity; the latter is made possible by inhibition of sphingosine 
kinase, an enzyme involved in a key steps of the synthesis of the adhesion proteins (Xia et al 1999). 
Synthetic HDLs, obtained through the association between phosphatidylcholine and apoA-I, exert 
an inhibition on this cytokine-induced expression (Calabresi L 1997). Another anti-inflammatory 
effect of HDLs involves the transport of sphingosine-1-phosphate (S1P) a lipid mediator endowed 
anti-inflammatory properties at low concentration (Sato et al 2010).   
Anti-oxidative function  
LDL particles represent a major risk factor in atherogenesis after undergoing oxidative 
modifications (Steinberg 1997). The oxidation process induces several structural and 
compositional alteration in apoB. The presence of oxidized LDL and their accumulation in vessel 
wall play a pivotal role both in early and in late stages of atherogenesis. Ox-LDL and oxidized lipids 
can induce pro-inflammatory phenotypes which lead to endothelial dysfunction and apoptotic cell 
death, key steps in the initiation and progression of the atherosclerotic plaques (Navab et al 2011). 
HDL particles are heterogeneous in their capacity to protect LDL against oxidative modification 
(Bandeali et al 2012). HDL particles prevents LDL from free radical-induced oxidative damage 
through several mechanisms. The antioxidant effect is attributed to the capacity of HDLs to  
chelate transition metal, to extract lipids peroxidation products from oxidized lipoproteins or 
cellular membranes, to accept phospholipid-containing hydroperoxides from oxidized membranes 
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and to promote the transfer of hydroperoxides and other lipid peroxidation products from ox-LDL 
(Navab et al 2001). HDL particles contain several antioxidant enzymes that can be involved in the 
degradation of lipid hydroperoxides sush as paraoxonase-1 (PON1), LCAT, platetet-activiting factor 
acetylhydrolase (PSF-AH) and  lipoprotein-associated phospholipase A2 (Lp-PLA2). These enzymes 
may either directly prevent LDL oxidation or degrade oxidized bioactive products in LDLs.  In 
particular, the most prominent anti-oxidative capacity is associated with PON1, an enzyme located 
only on HDL and synthesized by the liver.  Over-expression of PON1 in mice confers enhanced HDL 
anti-oxidative capacity, and PON1 itself prevents LDL oxidation in vitro (Tward A 2002). Most 
importantly, HDLs isolated from mice lacking PON1 have reduced ability to prevent LDL oxidation. 
However it is very difficult to separate PON1 from other HDL components.  ApoA-I  itself exerts 
anti-oxidant effects. It plays an important role in the maintenance of the lipid environment in 
which enzymes such as PON1 and lecithin: cholesterol acyl transferase (LCAT) can operate. ApoA-I 
is essential in accepting oxidized lipids from ox-LDL as well as from cells and in creating a safe 
environment for the release of lysophospholipids and their subsequent transfer to the liver 
(Garner B 1998). Cell culture experiments showed that apoA-I is able to remove lipids from LDL 
and thereby to make LDL resistant to vascular cell-mediated oxidation and to prevent oxidized 
LDL-induced monocyte adherence and chemotaxis (Navab et al 2000). 
Hematopoietic function 
HDL particles play an important role in hematopoiesis. Several studies performed on ABCA1-/-
;ABCG1-/- mice showed that a deficit in cholesterol efflux transporters leads to leukocytosis, which 
is associated with atherosclerosis pathogenesis (Out et al 2008). In this model, fed a standard 
chow diet, an increase of myeloid cells, monocytosis, neutrophilia and eosinophilia were observed. 
When these animals were fed a high-fat diet , peripheral leucocytes and monocytes increased 
further. These results suggest a pivotal role for these transporters in the maintenance of myeloid 
cell homeostasis. Both ABCA1 and ABCG1 are expressed in hematopoietic stem and multipotential 
progenitor cells (HSPCs). A deficit in these transporters leads to an increase in the number of 
HSPCs. HDL particles are able to reverse the hyperproliferation of HSPCs in the absence of ABC 
transporters by promoting cholesterol efflux through passive aqueous cholesterol diffusion or 
other mechanisms. 
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ApoA-I is not expressed in hematopoietic stem cells and the apoA-I deficit in murine models does 
not lead to monocytosis and HSPCs ((Yvan-Charvet et al 2010)). The study performed on Ldlr-/-
apoA-I-/- mice fed high fat diet, showed an enlargement of lymph nodes and spleens in 
comparison with Ldlr-/- (Wilhelm et al 2009). This result suggests that apoA-I exerts a pivotal role 
in the regulation of peripheral lymphocyte proliferation in hypercholesterolemia. In particular, the 
deletion of apoA-I lead to an increase  of cholesterol in lymph nodes as well as to the expansion of 
all classes of lymph nodes cells with a significant increase in T cell proliferation and activation. 
When Ldlr-/-apoA-I-/-  mice were treated with apoA-I injections, the number of LN immune cells 
decrease. ApoA-I treatment increased T regulatory cells while decreasing the percentage of 
effector T cells. These results suggest that apoA-I is involved in control of T cell homeostasis in 
peripheral lymphoid organs through the modulation of the balance among T cells (Wilhelm et al 
2010).  The ability of HDL and of their main protein component apoA-I to suppress monocytosis, 
neutrophilia, monocyte and T-cell activation, stem cell mobilization and extra-medullary 
hematopoiesis appear to represent the key anti-atherogenic properties. 
Anti-thrombotic function 
Vascular endothelium damage leads to plateletes and coagulation factors activation. The main role 
of platelets is to seal the damaged vessel wall upon injury and to promote repair of the 
endothelium via the release of cytokines, chemokines, and growth factors (Broos et al 2011). 
Excessive platelet aggregation or activation causes thrombus formation. Dysfunction of 
endothelium can modify hamper its ability to participate in control of coagulation and fibrinolysis. 
LDL and ox-LDL, the pro-atherogenic lipoproteins are responsible for the increased susceptibility to 
thrombosis (Rosenson et al 1998). Conversely, HDL particles displaye  anticoagulant effects (Griffin 
et al 2001). HDL particles can affect both count and characteristics of platelets and modulate the 
risk of atherothrombosis events via the megakaryocyte- platelet hemostatic axis (Martin et al 
2012). Dyslipidemia does change the characteristics of megakaryocytes, which represent the 
precursor cells residing in the bone marrow. Several studies performed both in animal models and 
in humans, have shown that in hypercholesterolemia the megakaryocytes are significantly larger 
and have a higher mean ploidy in comparison with control condition (Pathansali et al 2001). High -
ploidy megakaryocytes generates larger and more active platelets (Corash et al 1987).  HDLs exert 
an inhibitory effect on platelet functionality  through their action on platelets and on endothelial 
cells. HDL particles inhibit platelet aggregation caused by both ADP and thrombina (Nofer et al 
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1996). Platelet aggregation is inversely correlated with HDL-C levels and with the extent of 
thrombosis (Naqvi TZ 1999).  The infusion of a mutant form of apoA-I, apoA-IMilano in rats and the 
administration to humans of rHDL that contain it result in the inhibition of platelet activation (Li D 
1999; Calkin AC 2009). 
In addition to their anti-aggregation activity, HDL particles also display anticoagulant effects, 
through the suppression of the coagulation cascade. The final step of this cascade is characterized 
by the conversion of prothrombin into thrombin, in the presence of factors Xa and Va.and of Ca
2+. 
This conversion occurs on the surface of membranes that contains anionic phospholipids.  HDLs 
have the ability to inhibit this conversion, blocking the transbilayer diffusion of anionic lipids, 
essential for the formation of the procoagulant complex (Epand et al 1994). Phosphatidylinositol 
4,5-bisphosphate plays a pivotal role in this process. Several complement system factors are able 
to active the coagulation cascade and HDL particle have demonstrated an inhibitory activity also at 
this level (Sulpice et al 1994). 
 
Endothelial function 
The endothelium significantly contributes to maintain vascular tone through the production of 
several substances. Among them, nitric oxide (NO) and prostacyclin (PGI2) play a central role. A 
decrease in their availability leads to endothelial dysfunction; several studies have shown that 
HDLs induce the increase of NO and PGI2 production both with direct and indirect mechanisms 
(Calabresi et al 2003). Studies performed on endothelial cells, demonstrated that HDL particles 
increase the abundance of endothelial NO synthase (eNOS) protein through both transcriptional 
and posttranslational modulation, prevent eNOS displacement from caveolae and promote the 
activation of eNOS  (Kuvin et al 2002). eNOS activation involves HDL binding  to SR-BI, which 
activates the phosphatidylinositol-3-kinase (PI3K)/Akt signalling pathway and the phosphorylation 
of endothelial nitric oxide synthase (eNOS) (Besler et al 2011). In addition, HDL can mediate eNOS 
activation through the interaction of sphingosine-1-phosphate (S1P) with its receptors.  S1P is a 
bioactive phospholipid associated with HDL, in which it is specifically bound to apolipoprotein M 
(apoM), which thus represents a vasculo protective constituent of HDL (Christoffersen et al 2001).  
Cultured endothelial cell experiments demonstrated that HDLs increase PGI2 though different 
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mechanisms. HDL can supply endothelial cells with arachidonate, that is a substrate for PGI2 
synthesis (Pomerantz et al 1985), or can activate a calciumsensitive (Tamagaki et al 1996), 
membrane-bound phospholipase that makes endogenous arachidonate available for PGI2 
synthesis (Van Sickle et al 1986). In vivo experiments support the relevance of HDL in promoting 
endothelium dependent vasodilatation. Studies performed on hypercholesterolemic apoE-
deficient mice demonstrated that  intravenous injections of synthetic HDL (sHDL) restore 
endothelium dependent dilation with a dose-dependent effect (Kaul et al 2004). In humans, 
plasma HDL-C concentration is a strong independent predictor of NO dependent peripheral 
vasodilation in healthy individuals as well as in hyperlipidemic, diabetic and coronary patients 
(Zhang et al 2000). The intravenous infusion of sHDL in subjects with hypercholesterolemia or with 
low HDL-C rapidly restores the altered endothelium dependent peripheral vasodilation through 
increased NO bioavailability  (Spieker et al 2002). 
Anti-apoptotic function 
Cell apoptosis in response to endothelial damage represents a pivotal feature in atherosclerosis 
and other vascular diseases.  HDL particles exert several anti-apoptotic properties that increase 
cell survival. Growth factor deprivation-related apoptosis of cells is inhibit by HDL. These 
lipoproteins support mitochondrial function, reduce reactive oxygen species, prevent the release 
of apoptotic signals, such as cytochrome C and suppressed the activation of caspase 3 and caspase 
9, a family of protease involved in programmed cell death (Suc et al 1997). By activating PI3K/Akt, 
HDLs  drive the expression of endothelial antiapoptotic Bcl-xl, and suppresses Bid, a pro-apoptic 
protein HDL mediates changes in the expression of genes through cell signaling and via NO 
production and through activation of surface receptors by the action of HDL-associated proteins 
and of bioactive lipids, including apolipoprotein J (apoJ) and S1P(Riwanto M 2013). It is likely that 
alternative anti-apoptotic mechanisms resulting from HDL-induced signaling are also at work. 
Overall, HDL has been demonstrated to suppress apoptosis in endothelial cells. Different 
proatherogenic factors such as tumor necrosis factor (TNFα) and oxLDL, can promote endothelial 
cell apoptosis, causing an increase of intracellular calcium that lead to cell death. This process is 
reversed by HDL, which prevent calcium increase (Suc et al 1997). HDL-associated 
lysophospholipids sphingosylphosphorylcholine and lysosulfatide protect endothelial cells from 
the effects of growth factors related to apoptosis, both by blocking the mitochondrial pathway of 
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apoptosis and by activating Akt. Moreover, lysophospholipid sphingosine-1-phosphate (S1P) 
increase cell survival (Nofer et al 2001). HDL promotes vascular cell migration, proliferation, 
survival and recruitment of endothelial progenitor cells (EPCs) to sites of vascular injury  (Di 
Angelantonio et al 2009). 
Anti-infectious function 
HDL particles are involved also in innate immunity  by their ability to modulate immune cell 
function. A large number of studies have demonstrated that lipoproteins act as anti-infectious, 
anti-parasitic, and anti-viral agents by binding microorganisms or compounds derived from 
microorganisms. When either lipopolysaccharides (LPS), from gram negative bacteria, or 
lipoteichoic acid (LTA), from gram positive bacteria, are incubated with whole blood from healthy 
humans, the majority of the LPS and LTA are bound to HDL. This interaction with HDL  prevents 
LPS and LTA interaction with toll-like receptors (TLR) and the resulting activation of macrophages 
(Khovidhunkit et al 2004). TLR activation of macrophages stimulates the production and secretion 
of cytokines and other signaling molecules, which if produced in excess can lead to septic shock 
and to death (Beutler et al 2003). Some studies have shown that HDLs, in addition to binding LPS, 
also facilitates the release of LPS that is already bound to macrophages, reducing macrophage 
activation. The capacity of LPS neutralization is related to both the lipid and protein components 
of HDLs. HDLs have also protective properties from parasitic infections. In addition, HDLs binds a 
wide variety of viruses and neutralizes their activity. HDL particles are able to kills Trypanosome 
brucei brucei and Trypanosome brucei rhdesiense, parasites that cause sleeping sickness, by 
creating ionic pores in endosomes. This effect is made possible when apolipoprotein L1 (apo-L1) 
(also known as trypanosome lytic factor) is present in specific sub-classes of HDL (Hajduk SL 1989). 
 
ATHEROSCLEROSIS 
Pathogenesis of Atherosclerosis  
Cardiovascular disease (CVD) is the main cause of death in worldwide; coronary disease, namely 
heart attacks and stroke, kills 4500 peopleevry day in Europe and more than 17 million people in 
the world (WHO 2011). Atherosclerosis is a complex multifactorial chronic disease with different 
etiologies that synergistically promote lesion development (Figure 6) (Roger et al 2012). Among 
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them, elevated plasma concentration of cholesterol, especially LDL-Cs, genetic predisposition, age, 
gender, smoking, hypertension, stress, poor dietary habits and physical inactivity, represent the 
major risk factors. The first step in atherosclerosis development is a damage to, or thickening of, 
endothelium, a permeable barrier between blood and tissues. Endothelial injury of arterial walls 
occurs mainly in large and medium arteries, characterized by the presence of curvatures, 
bifurcations and branches, subjected to low shear stress and disturbed blood flow (atherosclerosis 
prone areas)(Gimbrone et al 2000). In these atherosclerosis-susceptible sites, plasma cholesterol, 
mainly that circulating in LDLs, can accumulate in the sub-endothelial space of the arterial wall. 
When LDL particles become trapped in an artery, they can undergo modifications such as 
oxidation, enzymatic processing, desialylation and aggregation; the modified lipoproteins 
represent the primary source of lipid accumulation in atherosclerotic plaques (Krauss et al 2010). 
These alterations lead to the formation of pro-inflammatory particles inducing the expression of 
several cell surface adhesion molecules, chemokines and other mediators of inflammation. These 
conditions cause the migration of leucocytes from the circulation into the intima of the arterial 
wall. Once monocytes enter the intima, they differentiate into macrophages, under the influence 
of monocyte colony stimulating factor (M-CSF). Macrophages are the most abundant 
inflammatory cell type in plaques and have a central role in all stages of atherosclerosis 
development. At the beginning, the oxidation of LDL particles interfere with the interaction 
between LDLs and their receptors promoting the bind with scavenger receptors, SR-A and CD36, 
presented on the macrophage surface; with time these cells become laden with lipids. The 
uncontrolled up-take of ox-LDL, the excessive cholesterol esterification and the impaired 
cholesterol release, lead to the accumulation of CE; these are stored as lipid droplets resulting in 
the formation of foam cells, the major hallmarks of the early stage of atherosclerosis lesions (Ji et 
al 2011). Studies performed on mice lacking SR-A and CD36 receptors detected a modest decrease 
in atherosclerotic plaque (Suzuki H 1997). This early vascular lesion progresses further with the 
migration and proliferation of smooth muscle cells (SMC) from the media into the intima. These 
cells synthesize the bulk of the arterial extracellular matrix. 
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Figure 6. Reppresentation of normal human artery and artery with atherosclerotic plaque. 
Inflammation in Atherosclerosis 
Inflammation is a process that plays a pivotal role in both the initiation and the progression of 
atherosclerosis (Rosenfeld et al 2013). Macrophages represent the main inflammatory cells, but 
other kinds of cells are involved in atherogenesis including dendritic cells (DCs), mast cells and T 
cells. 
Intracellular cholesterol accumulated into macrophages can precipitate in the form of 
microcrystals able to activate an inflammasome, a cytosolic molecular machine that cleaves a 
proforma of interleukin (IL)-1 β, converting it into bioactive IL1 β that can be secreted by the cell 
(Duewell et al 2010). When released in the arterial intima, IL-1 β promotes the production of other 
pro-inflammatory molecules such as the cytokine IL-6 and the pro-inflammatory eicosanoid, PGE2 
(Libby et al 1988). IL-1 β can also stimulate the expression of leucocyte adhesion molecules and 
matrix-degrading metalloproteinases. In this way cholesterol accumulation begets inflammation 
and tissue remodeling. Macrophages produces inflammatory cytokines that stimulate the 
generation of endothelial adhesion molecules, protease and other mediators, wich recruit T cells, 
B cells and other macrophages into the lesion site (Galkina et al 2009).  
T lymphocytes are recruited in atherosclerotic lesions and are present at nearly all stages of their 
development. T cells are activated in atherosclerotic lesions by adhesion molecules and 
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chemokines. CD4+ T cells represent the most abundant T cells present in atherosclerotic lesions 
(Jonasson et al 1986). In the arterial vessel cholesterol accumulation and vascular inflammation 
lead to the differentiation of naïve CD4+T. T effector memory represent the subset of CD4+ T cells 
that support cytotoxic functions of CD8+T cells and produces cytokines such as IFNy and IL4. They 
respond to local peptide antigens producing pro-inflammatory cytokines and contribute to 
atherosclerotic lesions formation and plaque vulnerability. These cells are routinely found in 
atherosclerotic plaques where they sustain the inflammatory response (Hansson et al 2006). On 
the other hand, regulatory T cells (Treg) inhibit this process displaying a protective effect on the 
development of atherosclerosis. T cells are responsible for the regulation of the pro-inflammatory 
phenotype of macrophages, through the production of interferon (IFN) and of cytokines such as 
TGF-beta and IL-10. CD8+T lymphocytes are less abundant than CD4+ cells, but are involved as 
well as in atherosclerosis development. They exert several effects during the atherosclerotic 
process including direct cytotoxicity and secretion of pro-inflammatory cytokines.  
B lymphocytes are found in advanced atherosclerotic plaques, but their precise function is not 
known. These cells mediated adaptive immunity and can exert an atheroprotective role, in 
contrast to the pro-atherogenic role played by such inflammatory cells as monocytes and T-
lymphocytes (Hansson 2002). 
Plasmacytoid dendritic cells are a subset of dendritic cells that produces type I Interferon in 
response to virus; they present antigens on their surface and activate T cells (Reizis et al 2011) 
Dendritic cells have been observed in atherosclerotic lesions and in unstable plaques, suggesting 
that they are involved in atherosclerosis development in humans. Studies performed in 
atheroprone mice lacking plasmacytoid dendritic cells lead to the observation of a distinct 
decrease in lesion formation and a reduction of T cells infiltration in plaques (Döring  et al 2012). 
Mast cells contribute to innate and adaptive immunity and play an important function in 
inflammation while their products modulate the production  inflammatory mediators. In health 
conditions mast cells are seldom observed in vascular sites. Their numbers within the arterial wall 
increases during atherosclerosis. Mast cells contribute to plaque destabilization by producing 
proteases such as tryptase and chymase which lead to intra-plaque hemorrhage, macrophages 
and endothelial cells apoptosis, matrix degradation, vascular leakage; they also produce cytokines 
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and chemokines, which bring about the recruitment of leukocytes to the atherosclerotic lesions 
(Zardi EM 2014).  
Advanced Lesions in Atherosclerosis 
Macrophage foam cells contribute to the further growth and destabilization of the plaque through 
the  secretion of cytokines and chemokines, the production of reactive oxygen species (ROS), the 
presentation of immune activation markers to lymphocytes or to macrophage scavenger receptor, 
the generation of matrix-degrading proteases and the release of inflammatory debris into the 
atherosclerotic plaque core following necrosis or apoptosis (Randolph 2014). Cytokines and 
growth factors produced by macrophages and T cells stimulate migration and proliferation of 
vascular smooth muscle cells. The accumulation of these types of cells leads to the production of a 
complex of extracellular matrix composed of collagen, proteoglycans and elastin, eventually 
resulting in the formation of a fibrous cap (Libby 2000). When the macrophages loose the ability to 
accumulate more lipids, they degenerate and contribute to the formation of a necrotic core. Cell 
death can lead to necrosis by at least two mechanisms: apoptosis followed by defective phagocytic 
clearance (‘efferocytosis’) of the apoptotic cells and a process called primary necrosis (Libby et al 
2014). The necrotic core is formed mainly by a lipid pool of esters of cholesterol and dead 
macrophages, which cause an additional recruitment of inflammatory cells (Seimon et al 2009). 
The atherosclerotic process typically lies silent for months, years and even decades and may never 
result in clinical manifestations (Jonasson et al 1986). But once the surface of the plaque is 
damaged, thrombotic occlusion of the artery may ensue. Surface continuity can be damaged by 
fissuring (the so-called plaque rupture, observed in 60% to 80% of cases of acute coronary 
syndrome) or surface erosion (present in 20% to 40% of cases with coronary thrombosis (Farb et al 
1996). Recent studies suggest that the proportion of infarctions caused by rupture versus erosion 
is changing, with more cases due to erosion and fewer to overt plaque rupture (Falk et al 2013). 
The sites of fatal disruption are characterized by a thin fibrous cap (<50–60 micrometers), 
depletion of SMC necessary to repair and maintain collagen, increase of inflammatory activity and 
heightened amounts of proteolytic enzymes  (van der Wal et al 1994). Therefore, inflammatory 
stimuli such as local immune reactions might activate macrophages, mast cells and T cells to 
release cytokines that inhibit cap formation and proteases that digest fibrous components of the 
cap. Much interest has focused on the collagenolytic action of matrix metalloproteinases and 
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cysteine proteases in the plaque. (Sukhova et al 1998). Fissuring or erosion can lead to thrombus 
formation resulting in myocardial infarction and stroke (Virmani R 2002).  
Murine models of atherosclerosis 
Rodents, in particular mice, are the most useful experimental species for the study of several 
diseases, including atherosclerosis (Hofker MH 1998). The use of murine models presents both 
advantages and limitations (Table 2). Mice and humans show differences in parameters that 
influence atherogenesis and the distribution of the lesions. Humans present more atherosclerotic 
plaques in the coronary arteries, carotids and peripheral vessels such as the iliac artery. 
Conversely, mice manifest more frequently lesions in the aortic sinus, the site from which the 
ascending aorta originates. This area, due to its shape and position (next to the heart and exposed 
to high pressure with disturbed blood flow) proves to be subject to lipids accumulation. In mice, 
lesions can be present at other sites such as the arteries that pass from the aortic arch 
(brachiocefalic artery, left and right carotid arteries, right succlavia artery), the renal arteries and 
the aortic valves (Coleman et al 2006). The atherosclerotic lesions of mice do not exhibit such 
features associated with human disease as the unstable plaque with overlying thrombosis nor are 
characterized by the development of a thick fibrous cap.  
Despite its limitations, the mouse represents the favorite species for the study of atherosclerosis, 
because it displays several advantages such as the ease of breeding, the ease of genetic 
manipulation and the ability to monitor atherogenesis whitin a reasonable time frame. In addition, 
mice and humans are genetically quite similar and share the same set of genes controlling 
lipoprotein metabolism. The reference mice, named wild-type, are characterized by a different 
lipoprotein profile compared to humans. In this model plasma cholesterol is essentially associated 
with the HDL fraction: therefore in the absence of atherogenic plasma lipoproteins, this mouse is 
resistant to atherosclerosis development. In addition, wild-type mice do not express CETP, which 
represent a potential target for atheroprotection in humans (Davidson et al 2010). About 30 years 
ago, it was observed that a variety of mice, named C57BL/6 for the colour of their fur, was able to 
develop moderate atherosclerotic lesions at the aortic sinus level, when fed with a diet high 
content in cholesterol. In more recent years, using the technique of homologous recombination, it 
was possible to generate murine models able to develop severe lesions along the arterial tree, 
both upon dietary challenge and spontaneously. 
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Advantages Limitations 
Ease of breeding/size of litters No coronary lesions 
Multiple imbred strains Only partial resembiance to human 
Short reproductive cycle Limitated tissue availability and technical 
difficulties due to small size 
Relatively low cost of maintenance Wild-type relatively atherosclerosis resistant 
Well-know genome Monotypic HDL 
Ease of genetic manipulations to study the role 
of cell types or proteins on atherosclerosis 
 
Atherosclerosis develops over relatively short of 
time 
 
Useful for non invasive imaging (MRI, Pet; CT, 
Ultrasound) 
 
 
Table 2. Advantages and limitation of murine model of atherosclerosis 
EKO mouse 
In 1992 two different groups simultaneously generated the EKO mice by homologous 
recombination in embryonic stem cells. The EKO mouse, deficient in the apolipoprotein E, 
represents the most widely studied animal model for atherosclerosis (Zhang SH et al 1992)(Plump 
AS et al 1992). The deletion of the E gene leads to severe hypercholesterolemia with the 
development of spontaneous atherosclerotic lesions.  
ApoE,  a 34-kDa 299 amino acid long protein, is synthesized mainly in the liver but also in different 
cells types, including macrophages. This protein represents a constituent of plasma lipoproteins 
and plays an essential role in several anti-atherogenic functions through different mechanisms. 
ApoE is involved in the maintenance of cholesterol homeostasis, it serves as the ligand for the 
receptor-mediated up-take by the liver of circulating CMs, VLDL and their remnants, after their 
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binding to LRP and LDLR. This apolipoprotein exerts important functions in cholesterol metabolism 
and transport both stimulating reverse cholesterol transport and activating enzymes involved in 
lipoprotein metabolism such as hepatic lipase HL, CETP and LCAT. The process of cholesterol efflux 
is essential to maintain cholesterol homeostasis in cells that are incapable of limiting their uptake 
of lipids. Recent studies demonstrated that the secretion of apoE by macrophages stimulates 
cholesterol efflux via ABCA1.  ApoE displays additional anti-atherogenic functions through variuos 
mechanisms including the inhibition LDL oxidation, the prevention of platelet aggregation and  the 
reduction of the proliferation of T-lymphocytes, endothelial cells and SMCs (Greenow et al 2005).   
EKO mice fed chow diet, a diet that contains low amount of fat and is almost free of cholesterol, 
display total cholesterol levels at least five-fold higher than their wild-type counterparts (300-500 
mg/dl vs 100 mg/dl). In these animals cholesterol is mostly concentrated in CM and VLDL fractions 
and they develops spontaneous vascular atherosclerotic lesions. Over time, these lesions become 
more complex. When apoEKO mice are maintained with high-fat diet (a diet containing 0,2% 
cholesterol and 21% milk fat), they display a significant increase in plasma lipids with cholesterol 
about twenty times higher(> 1000 mg/di) then the animals of the control group. Furthermore, the 
challenge diet induces accelerated and more severe atherosclerotic lesions. The lesions of animals 
fed high fed diet are richer in foam cells, while animals fed chow diet show complex cellular 
lesions (Imazuimi et al 2011). Foam cells lesions have been observed at 8 to 10 weeks of age in 
EKO fed chow diet. After 15 weeks intermediated plaque are present, containing spindle-shaped 
cells, in particular SMC. After 20 weeks, fibrous plaques are evident containing SMC, extracellular 
matrix and an overlying fibrous cap. This time course is accelerated by the high fat diet, with the 
more advanced lesions in these mice containing cholesterol crystals, a necrotic core and 
calcifications (Nakashima et al 1994).   
A-IKO mouse 
Apo A-I is constituted of 243 amino acid residues organized in amphipatic alpha helices, and is the 
main constituent of HDL, being essential for the biogenesis of these particles. ApoA-I plays a 
structural role in HDL and contributes as well as to to their anti-atherosclerotic properties. It is 
synthesized and secreted by liver and intestine and is metabolized by the kidney. Hepatic apoA-I is 
synthesized as a preproprotein that is cleaved intracellularly by a signal peptidase. The resulting 
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propeptide is secreted before cleavage by bone morphogenic protein-1 in a process that is 
facilitated by procollagen C-proteinase enhancer (Chau et al 2007).   
Epidemiological studies have demonstrated that HDL particles play a pivotal role against the 
development of atherosclerosis and cardiovascular disease, and high plasma levels of HDLs are 
inversely correlated with the incidence of these pathologies. This relationship can be explained, at 
least in part, with the atheprotective effects of HDL lipoproteins.  Its major protein component 
apoA-I mediates many HDL functions.  
Over-expression of human apoA-I in C57Bl/6 mice, characterized by high plasma apoA-I and HDL 
levels, protects from atherosclerosis development (Rubin et al 1990).  Another study, performed 
on transgenic mice over-expressing human apoA-I and with deletion of ApoE, showed a distinct 
decrease of atherosclerosis development, associated with a reduction in total cholesterol (577 
mg/dl vs 663 mg/dl of EKO mice) and an increase in HDL-cholesterol (105 mg/dl vs 50 mg/dl) 
(Plump et al 1994)(Pàszty et al 1994). 
Mice lacking apoA-I (A-IKO) were generated in order to verify if a decrease of HDL lipoproteins can 
be involved in an increased predisposition to atherosclerosis development. These animals showed 
a marked reduction both in total plasma cholesterol and in HDL-cholesterol levels. In addition, the 
deficit of apoA-I led to increase in HDLs of apoA-IV and apoE, which under physiological conditions 
represent minor components of the particles. In apoA-IKO fed chow diet, the absence of apoA-I 
results in a reduction of total plasma cholesterol in comparison with the control group (23,7 mg/dL 
vs 90,2 mg/dL) and HDL-cholesterol (20 mg/dL vs 85,3 mg/dL). In mice between 8 and 15 months 
of age , fed chow diet, no atherosclerotic lesions were observed, while in animals fed the 
atherogenic diet for 32 weeks, only some pre-atherosclerotic lesions, such as foam cells at aortic 
valve level, were identified (Li H 1993).  These studies demonstrated that in murine models, the 
decrease of apoA-I alone does not lead to atherosclerosis development in mice fed either chow 
diet or high fat diet. 
LDLrKO/A-IKO mouse 
LDLrKO represents another mouse model used to investigate atherosclerosis. When fed chow diet, 
this model develops atherosclerotic lesions only in older animals (Hartvigsen et al 2007). To obtain 
significant plaques the feeding of an atherogenic diet is necessary. Several studies have been 
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performed on the LDLrKO/apoA-IKO (dKO) murine model. After being maintained with 
atherogenic diet for 16 weeks, LDLrKO/A-IKO mice showed a lower increase of total plasma 
cholesterol (546 mg/dL female and 652 mg/dL male) in comparison with LDLrKO mice (2341 mg/dL 
female and 2226 mg/dL male). DKO animals develop  markedly aortic atherosclerosis in response 
to an atherogenic diet. Furthermore, this model shows massive cholesterol accumulation in the 
skin, accompanied by an increase in dermal thickness, by hair loss and macrophage infiltration  
(Zabalawi M 2003). 
Another study performed on the same model, showed, after 10 week on an atherogenic diet, an 
enlargement of skin draining lymph nodes in comparison with LDLR-/- animals. In these lymphoid 
organs an accumulation of cholesterol and an expansion of the populations of T, B, dendritic cells 
and macrophages were observed (Wilhelm et al 2009).  
The administration of lipid-free human apoA-I decreases inflammation and cholesterol 
accumulation in the skin and skin draining lymph nodes of LDLR-/-;apoA-I-/- mice. In particular,  
the skin showed a reduction of cellularity and the restoration of skin architecture, morphology and 
composition. Furthermore, after the treatment a significant increase in the lymph nodes T reg 
population with a simultaneous reduction of T effectors were observed (Wilhelm et al 2010). 
Murine models of coronary atherosclerosis 
As mentioned previously, mouse models present limitations for the study of human cardiovascular 
disease. ApoEKO and LDLRKO, the traditional murine models of atherosclerosis, do not develop 
spontaneously coronary atherosclerotic plaques. However, in animals with additional genetic 
manipulation these lesions may be observed. ApoEKO/LDLRKO mice, maintained for 7 months 
with high fat diet, exhibit atherosclerotic plaque in coronary arteries and myocardial infarction, in 
particular when subjected to stress (Caligiuri et al 1999). Double knockout mice with homozygous 
null mutations for apoE and SR-BI genes, fed chow diet,  display severe occlusive lesions in 
coronary artery at 5 weeks of age and develop multiple myocardial infarctions and cardiac 
dysfunctions including enlarged heart, reduced ejection fraction and contractility, and ECG 
abnormalities. All animals die by 8 weeks of age (Braun et al 2002). Also the SR-BIKO/LDLRKO 
animals, when fed a high fat diet, have accelerated atherosclerosis development at the aortic sinus 
and show coronary atherosclerosis (Fuller et al 2014). 
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Several studies have been showed that the concentration of HDL cholesterol (HDL-C) 
is inversely related to the risk of having a cardiovascular event. Moreover, increasing 
the levels of HDL lipoproteins and their main protein component apoA-I, which is 
directly involved in most of the anti-atherogenic properties of HDL, have been 
associated with a reduction in experimental atherosclerosis and a plethora of 
beneficial actions of HDL have been demonstrated in animal models. In this 
paradigm, HDL-C has been considered to be a marker of the potentially 
cardioprotective functions of HDL. However, recent studies have suggested that the 
mere concentration of HDL-C cannot always reflect HDL function, with growing 
evidence that under some conditions HDL functions can be compromised despite 
high concentration of HDL-C. Thus, a more complicated picture of the role of HDL 
apoA-I in cardiovascular disease prevention has emerged, also from recent studies 
performed in animal models where mice with target deletion of the murine apoA-I 
gene does not lead to a greater atherosclerosis susceptibility. For this reason there is 
a need for more critical evaluation of the different proposed functionalities of HDL, 
both in animals models and in the clinic. The aim of my project was to determine the 
effects of apoA-I on atherosclerosis development, phenotype, inflammation and 
immune function through the use of genetically modified mice deprived of, or 
overexpressing, apoA-I, in apoEKO background. 
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Mice 
Procedures involving animals and their care were conducted in accordance with 
institutional guidelines that are in compliance with national (D.L. No. 26, March 4, 
2014, G.U. No. 61 March 14, 2014) and international laws and policies (EEC Council 
Directive 2010/63, September 22, 2010: Guide for the Care and Use of Laboratory 
Animals, United States National Research Council, 2011). The experimental protocol 
was approved by the local authorities (Progetto di Ricerca Protocollo 2012/4). 
C57Bl/6 (WT) and apoE knockout (EKO) mice were purchased from Charles River 
Laboratories (Calco, Italy). ApoE/apoA-I double knockout mice (EKO/A-IKO) and 
apoE/apoA-I double knockout mice overexpressing the human isoform of apoA-I (hA-
I/EKO/A-IKO) were obtained by multiple crosses between EKO mice and apoA-I 
knock-out mice hemizygous for the expression of human apoA-I, previously 
generated in our lab. 
Mouse apoE (For 5’-GCCTAGCCGAGGGAGAGCCG-3’; Rev1 5’-
TGTGACTTGGGAGCTCTGCAGC-3’; Rev2 5’-GCCGCCCCGACTGCATCT-3’) and mouse 
apoA-I specific primers (For 5’-CCTTCTATCGCCTTCTTGACG-3’; Rev1 5’-
GTTCATCTTGCTGCCATACG-3’; Rev2 5’-TCTGGTCTTCCTGACAGGTAGG-3’) were used 
to screen by PCR the dKO and hA-I mouse lines. 
Human apoA-I expression was assessed by Western blot analysis on mouse plasma, 
using a specific goat polyclonal antibody (cod. 600-101-109, Rockland 
Immunochemicals Inc. Limerick, PA, USA). 
Mice were maintained under standard laboratory conditions (12 hours light cycle, 
temperature 22°C, humidity 55%), with free access to standard rodent chow (4RF21, 
Mucedola, Settimo Milanese, Italy) and tap water from weaning (8 weeks of age) to 
30 weeks of age. 
 
Harvesting of tissues 
Mice were sacrificed at 30 weeks of age under general anaesthesia with 2% 
isoflurane (Forane, Abbot Laboratories Ltd, Illinois, USA). In advance of that, after an 
overnight fast, blood was collected, under 2% isofluorane anaesthesia, from the 
retro-orbital plexus into tubes containing 0.1% (w/v) EDTA and centrifuged in a 
microcentrifuge for 10 minutes at 5900 g at 4°C to obtain plasma samples. 
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Blood was removed from the body by perfusion with phosphate-buffered saline 
(PBS). For histological analyses, hearts were harvested, fixed in 10% formalin for 30 
minutes and transferred into PBS containing 20% sucrose (w/v) overnight at 4°C 
before being embedded in OCT compound (Sakura Finetek Europe B.V., Alphen aan 
den Rijn, The Netherlands) and stored at -80°C. 
From a first set of mice, one half of the spleen, as well as half of axillary and inguinal 
lymph nodes were harvested and immediately processed for flow-cytometry 
analysis. Contralateral skin draining lymph nodes (axillary and inguinal lymph nodes), 
and half the spleen were snap-frozen in liquid nitrogen for subsequent RNA-seq 
analysis. 
From a second set of mice, axillary and inguinal lymph nodes, half of the spleen and 
liver were immersion-fixed in 10% formalin for 24 hours, dehydrated in a graded 
scale of ethanol, and paraffin embedded. Contralateral axillary and inguinal lymph 
nodes and half of the spleen were immersion-fixed in 10% formalin for 24 hours and 
transferred into PBS containing 20% sucrose (w/v) overnight at 4°C before being 
embedded in OCT compound and stored at -80°C. 
Skin biopsies were harvested from two different anatomical areas (thoracic and 
abdominal regions), deep up to the muscle layer to be sure to include also 
hypodermis, and processed for both light and transmission electron microscopy for 
the evaluation of skin morphology at the structural and ultrastructural level. 
 
Lipid/lipoprotein analyses 
Total cholesterol was measured by an enzymatic method (ABX Diagnostics, 
Montpellier, France). 
Plasma lipoprotein distribution was analyzed in plasma pools from three fasting mice 
for each mouse line. Plasma lipoproteins were separated by Fast Protein Liquid 
Chromatography (FPLC) with size exclusion method that separate lipoproteins 
according to their size. One  Superose 6 10/300 (Pharmacia)  column was utilized and 
2 mM pH 7.4 Phosphate buffer containing 0.15 M NaCl, 0,03% EDTA and 0,02% NaN3 
was used as mobile phase. Plasma samples (500 µl) were introduced into the injector 
and carried into the column by the flowing solvent. Column was equilibrated with 
buffer before loading sample. Once in the column, the sample mixture separates as a 
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result of different components adhering to or diffusing into the gel. As the solvents is 
forced into the chromatographic bed by the flow rate, the sample separates into 
various zones of sample components and were detected by UV absorption at 280 
nm. FPLC is performed at 0.5 mL/min constant flow rate for 120 minutes at room 
temperature. Forty fractions of 0.8 ml each were collected in 96 wells-plate and total 
cholesterol content was measured in each fraction as previously described. 
Plasma hApoA-I concentration was determined by immunoturbidimetric assays, 
using an antiserum specific for human apoA-I (LTA, Italy). Coomassie staining was 
used to quantify plasma murine ApoA-I and to confirm the immunoturbidimetric 
quantification of hApoA-I. 
Moreover, lipids were extracted from skin with a mixture of chloroform:methanol, 
lipid extracts were dried and the lipids dissolved using Triton X-100. Total and 
unesterified cholesterol, phospholipid and triglyceride contents were quantified by 
enzymatic assays and expressed as μg/mg of tissue. Total cholesterol, unesterified 
cholesterol, triglycerides and phospholipids were quantified by enzymatic methods 
(ABX Diagnostics, Roche Molecular Biochemicals, ABX Diagnostics, B.L. Chimica, 
respectively). Esterified cholesterol content was calculated as total cholesterol – 
unesterified cholesterol. 
 
En Face analysis 
Aorta was rapidly dissected from the aortic root to the iliac bifurcation, 
periadventitial fat and connective tissue were removed as much as possible. Aorta 
was longitudinally opened, pinned flat on a black wax surface in ice cold PBS and 
photographed unstained for plaque quantification. 
Aorta images were recorded with a stereomicroscope-dedicated camera (IC80 HD 
camera, MZ6 microscope, Leica Microsystems, Germany) and analyzed using ImageJ 
image processing program (http://rsb.info.nih.gov/ij/). An operator blinded to 
dietary treatment quantified the atherosclerotic plaques. 
 
Histology 
Heart. Serial cryosections (7 μm thick) spanning the entire length of the heart were 
cut. Every fifth slide was fixed and stained with hematoxylin and eosin (Bio-Optica, 
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Milano, Italy) to detect plaque area both at the aortic sinus and the coronary arteries 
level. Plaque area at the aortic sinus was calculated as the mean area of those 
sections showing the three cusps of the aortic valves. Adjacent slides were stained 
with Oil Red O to quantify intraplaque neutral lipid deposition (Sigma-Aldrich, St. 
Louis, MO, USA). The Aperio ScanScope GL Slide Scanner (Aperio Technologies, 
California, USA) was used to acquire digital images that were subsequently 
processed with the ImageScope software. A blinded operator to dietary treatment 
and genotype quantified plaque size. 
Spleen, axillary and inguinal lymph nodes. Serial sections (4 μm thick) were obtained 
and stained with hematoxylin and eosin (Bio-Optica, Milano, Italy). A dedicated 
subset of spleen, axillary and inguinal lymph nodes was additionally included in OCT 
and cryosections (7 micron thick) were stained with Oil Red O to detect neutral lipid 
accumulation. Lipid deposition was measured as the percent of Oil Red O positive 
area over the total area. by the ImageScope software. 
Skin. Skin samples (5 x 5mm2) were immersion-fixed in 4% paraformaldehyde 
buffered with PBS 0.1 M (pH 7.4) for 5hours at room temperature (RT), dehydrated 
in a graded scale of ethanol and paraffin embedded. Sections, 4 μm thick, were cut 
using a rotary microtome (RM2245, Leica Microsystems GmbH Wetzlar, Germany) 
and stained with hematoxylin and eosin. At least five non-consecutive slides for each 
sample were observed to evaluate the skin structure by a Nikon Eclipse E600 
equipped with a Nikon digital camera DXM1200 (Nikon, Tokyo, Japan). The 
morphometric analysis of the skin of the four mouse lines was performed on 
hematoxylin and eosin-stained sections. Areas of epidermis, dermis, and hypodermis 
were separately measured on 10 slides per animal (from 3 mice of each genotype) 
using the software Image Pro-Plus (version 4.5.019; Media Cybernetics Inc., Silver 
Spring, MD, U.S.A.). Dermis/epidermis area ratio and hypodermis/epidermis area 
ratio excluding the dermal compartment were also calculated. 
 
Transmission electron microscopy 
Bioptic fragments (2 x 2mm2) were immersion-fixed overnight, at 4°C, in 3% 
glutaraldehyde diluted in 0.1 M Sorensen phosphate buffer (pH 7.4), washed three 
times for 30 min each with Sorensen phosphate buffer, and post-fixed in 1% Osmium 
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Tetroxide. After dehydration through an ascending series of ethanol solutions, 
samples were embedded in Durcupan (Durcupan, Fluka, Milan, Italy). Semithin 
sections, 2 μm thick, were stained with toluidine blue. Ultrathin sections were 
obtained with an Ultracut ultramicrotome (Reichert Ultracut R-Ultramicrotome, 
Leika, Wien, Austria) and stained with uranyl acetate/lead citrate before observation 
by a Jeol CX100 transmission electron microscope (Jeol, Tokyo, Japan). 
 
Flow-cytometry analysis 
Several leukocytes populations were investigated by flow cytometry. CD4+ T 
lymphocyte subsets, T naïve (TNAIVE); T Central Memory (TCM), T Effector Memory 
(TEM), were analysed by flow cytometry in peripheral blood, spleen and lymph 
nodes.  In addition, the attention were also focused on monocytes, monocytoid as 
well as plasmacytoid dendritic cells and B cells both in blood and secondary 
lymphoid organs. For flow-cytometry analysis a Calibur Flow Cytometer (BD 
Biosciences)with two lasers was used. The panels consisted of the subsequent 
cellular surface markers: CD4 (PE YTS 191.1.2, Immunotools), CD44 (FITC, IM7, BD 
Pharmigen), CD62L (APC, mMEL-14, BD Pharmigen), Ly-6C (FITC AL-21, BD 
Pharmigen), CD115 (APC AF598, eBioscience), CD11b (PE M1/70.15, Immunotools), 
CD11c (APC HL3, BD Pharmigen), B220 (PerCP Cy5,5 RA3-6B2, BD Pharmigen), CD19 
(FITC 1D3, BD Pharmigen) and CD5 (APC 53-7.3, BD Pharmigen). All data were 
acquired in FCS format and were processed and analyzed using FCS Express V3 
Research edition (De Novo Software, Inc; www.denovosoftware.com). CD4+CD44-
CD62L+ are indicated as T naïve,  CD4+CD44+CD62L- are indicated as T effector 
memory cells and CD4+CD44+CD62L+  are indicated as T central memory cells. 
CD11b+CD115+Ly6Clo are indicated as patrolling monocytes and 
CD11b+CD115+Ly6Chi as inflammatory monocytes. CD11chiCD11b+B220lo are 
indicated as myeloid while CD11cloCD11b-B220hi as plasmacytoid dendritic cells. 
CD19+CD5+ are indicated as B1a cells and CD19+CD5- as B1b cells. 
 
RNA extraction from lymphoid organs 
Total RNA was isolated from axillary/inguinal lymph nodes and spleen of EKO/A-IKO 
and hA-I/EKO/A-IKO mice using the NucleoSpin RNA extraction kit (Macherey-Nagel, 
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Duren, Germany) according to the manufacturer’s instructions. RNA concentration 
and purity were estimated evaluating the ratio of optical density at 260 and 280 nm 
(Nanodrop 1000, ThermoScientific, Wilgminton, DE). RNA integrity was checked by 
electrophoresis in a 1.7% TAE gel stained with ethidium bromide (Sigma-Aldrich, 
Seelze, Germany). 
 
RNA-seq analysis 
For RNA-Seq analyses, the quality of the mRNA was also tested using the Agilent 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). RNA samples were 
processed using the RNA-Seq Sample Prep kit from Illumina (Illumina, Inc., CA, USA). 
8 to 9 tagged libraries were loaded on one lane of an Illumina flowcell, and clusters 
were created using the Illumina Cluster Station (Illumina, Inc., CA, USA). Clusters 
were sequenced on a Genome Analyzer IIx (Illumina, Inc., CA, USA) to produce 50nt 
single-end reads.   
 
Bioinformatics analysis 
Pre-processing of reads. A custom script implementing strict quality filters based on 
the provided base call quality scores was used to trim sequence reads prior to 
assembly. Reads were iteratively trimmed from the 3’ end until all of the following 
conditions were satisfied: 
1. the median quality score (Qscore) of upstream bases was >25 
2. less than 3 bases with Qscore <= 10 and less than 5 bases with Qscore <=20 were 
present in the upstream sequence  
3. the cumulative error probability in the upstream region was below 5E-3. 
Only reads longer than 40nt in length after trimming were retained. 
Differential gene expression. Reads were mapped to the mouse genome (mm10) 
using the TopHat2 software (23618408) in conjunction with the reference Refseq 
annotation (excluding tRNA and rRNA genes). Differentially expressed genes were 
identified using CuffDiff (23222703).  
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Functional association analysis 
Lists of differentially expressed genes were uploaded into the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) v6.8 Beta (https://david-
d.ncifcrf.gov/) (Nature Protocols 2009; 4(1):44 & Nucleic Acids Res. 2009;37(1):1) to 
determine differentially regulated pathways using the mouse genome as reference 
background. Data were analyzed with the Functional Annotation Chart tool using the 
KEGG pathway or the Biological Process Gene Ontology term. Cutoff criteria used 
were either a Benjamini multiple testing correction p-value less than 0.05 or a 
modified Fisher’s exact (EASE score) p-value of less than 0.01. 
 
Statistical analyses 
Data are expressed as mean ± SD. Group differences were tested for statistical 
significance by  ANOVA, followed by Tukey post hoc test. A value of p<0.05 was 
considered statistically significant. statistical analyses were performed using the 
SYSTAT software (Version 13; Systat Software, Inc., Chicago, IL). 
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Plasma cholesterol profile and apoA-I concentration 
Plasma cholesterol concentration in EKO/A-IKO mice was significantly increased 
compared with that of WT mice (109.24±10.18 mg/dl vs. 83.91±5.97 mg/dl, 
respectively; p<0.01), and approximately 4-fold lower than the concentration 
observed in EKO mice (109.24±10.18 mg/dl vs. 397.94±31.09 mg/dl; p<0.01) and hA-
I/EKO/A-IKO mice (109.24±10.18 mg/dl vs. 441.31±137.37 mg/dl; p<0.01). 
To evaluate the cholesterol distribution among the different lipoprotein classes, 
mouse lipoproteins were separated by FPLC and the cholesterol content was 
measured on the collected fractions. The cholesterol profile of WT mice was 
characterized by a cholesterol distribution almost exclusively confined to the HDL 
fraction, whereas EKO mice displayed a major cholesterol accumulation in the 
VLDL/LDL fractions and lower HDL-cholesterol levels compared WT mice. In EKO/A-
IKO mice, HDL-cholesterol was almost absent and the cholesterol accumulation in 
the VLDL/LDL fractions was lower than that found in EKO mice. hA-I/EKO/A-IKO mice 
were on the contrary characterized by a large HDL-cholesterol peak and by a marked 
presence of VLDL/LDL particles, although less prominent than in EKO mice (Figure 7). 
 
 
Figure 7. Cholesterol FPLC profile in mice plasma. Plasma lipoprotein were separated 
by size exclusion chromatography and the cholesterol content was measured in each 
fraction. 
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ApoA-I concentration in EKO mice was approximately 2.6-fold reduced compared 
with that measured in WT mice (39.3±4.5 mg/dl vs 103.2±12.7 mg/dl, respectively). 
In contrast, hA-I/EKO/A-IKO mice showed a concentration of apoA-l 5.4-fold higher 
than that found in EKO mice and 2-fold higher than that found in WT mice 
(212.1±75.5 mg/dl). As expected, plasma apoA-I was completely depleted in EKO/A-
IKO mice. 
 
Atherosclerosis evaluation 
To investigate the role played by different levels of apoA-I during atherosclerosis 
development, EKO/A-IKO, hA-I/EKO/A-IKO, EKO and WT mice were fed chow diet for 
22 weeks. Atherosclerotic burden was quantified at the aortic sinus by histology and 
in the whole aorta by en-face analyses. 
 
Figure 8. Histological characterization of plaques in the aortic sinus stained both with 
hematoxylin&eosin (A-H) and Oil Red O (I-P) in all experimental group fed with chow 
diet for 22 weeks (Bar = 250 μm) 
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Aortic sinus histology. The deficiency of apoA-I caused a worsening in plaque 
development at the aortic sinus of in EKO/A-IKO mice compared with EKO mice 
(3.2±0.7 x 105 μm2 vs. 6.2±0.5 x 105 μm2, respectively; p<0.001). Conversely, hA-I 
overexpression dramatically reduced atherosclerotic plaque development at the 
aortic sinus of hA-I/EKO/A-IKO mice compared with both EKO/A-IKO (0.5±0.3 x 105 
μm2 vs. 6.2±0.5 x 105 μm2, respectively; p<0.001) and EKO mice (0.5±0.3 x 105 μm2 
vs. 3.2±0.7 x 105 μm2, respectively; p<0.001). As expected, no plaques were observed 
at the aortic sinus of WT mice (Figure 8).  
 
 
 A                                 B 
Figure 9. Histological characterization of plaques in the common coronary arteries 
stained with hematoxylin&eosin in EKO mice (A) and EKO/A-IKO mice (B). 
 
Coronary arteries histology. In addition, preliminary data suggest that EKO/A-IKO, 
but not apoEKO develop significant atherosclerotic plaques at the common coronary 
arteries (76,25±8,62% and 0±0%, respectively) (Figure 9 A-B). 
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En Face analysis. En face analysis demonstrated that apoEKO/apoA-IKO and apoEKO 
mice had a similar extent of atherosclerotic plaques at the aortic arch (6.9±5.6%, 
7.2±5.5%, respectively; p>0.05) whereas no plaque development was observed at 
the aortic arch of hA-I/EKO/A-IKO and WT mice. No atherosclerosis was observed in 
thoracic and abdominal aortic segments, regardless of genotype (Figure 10). 
 
 
Figure 10. En face analysis of the whole aorta in all experimental groups. 
 
Skin phenotype 
The skin of EKO/A-IKO animals showed macroscopic alterations that were not 
present in all the other experimental groups (Figure 11). Particularly, in these mice, 
hair loss and a pale/yellowish color of the skin was observed, mainly at the ventral 
region. No ulcerated skin lesions and excoriations were present (Figure 11).  
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Figure 11. Macroscopic representation of the cutaneous phenotype. 
 
Light microscopy analysis confirmed a great reduction of hair follicles in EKO/A-IKO 
mice if compared with WT, EKO and hA-I/EKO/A-IKO mice (Figure 12 A-B). On the 
other hand, epidermis showed comparable features and structure in all the 
considered groups. Dermis of EKO and hA-I/EKO/A-IKO mice was not different from 
that of WT mice (Figure 12 C D). In EKO/A-IKO mice, the dermis was thickened. 
Semithin sections revealed the presence of cholesterol clefts in papillary dermis 
(Figure 12 E) and foam cells accumulation in reticular dermis (Figure 12 F).  
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Figure 12. Skin histology. Light microscopy analysis. Representative 
photomicrographs of mouse skin. (A–D): paraffin sections after haematoxylin and 
eosin staining; (E and F): araldite semithin sections after toluidine blue staining. (A): 
WT mice; (B): EKO mice; (C): hA-I/EKO/A-IKO mice; (D–F): EKO/A-IKO mice. In (D) 
arrows indicate leukocyte infiltration; arrowheads indicate in (E) cholesterol clefts 
and in (F) foam cells. Bars: (A–D): 60 μm; (E): 15 μm; (F): 10 μm. 
 
Quantification of the skin lipid content of WT and EKO/A-IKO mice showed a strong 
accumulation of both unesterified and esterified cholesterol in EKO/A-IKO mouse 
skin (Table 3). 
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 WT EKO/A-IKO 
Total cholesterol 1.53±0.43 7.69±1.90* 
Unesterified cholesterol 1.43±0.41 5.96±1.42* 
Esterified cholesterol 0.10±0.08 1.73±0.53* 
Phospholipids 3.85±0.97 6.24±2.15 
Triglycerides 14.98±7.69 22.31±13.44 
 
Table 3. Skin lipid content of C57/Bl6 and A-IKO/EKO mice.  
 Data are expressed as μg of lipid/mg of tissue. Results are shown as mean±SD (n=5), 
*p<0.01 vs C57BL/6 
 
Immunohistochemical analysis revealed just some scattered CD3-positive cells 
localized in the papillary dermis in the skin of WT mice (Figure 13 A), while, in EKO/A-
IKO mice, CD3-positive cells were present in the papillary dermis and were organized 
in clusters in the reticular dermis, especially close to foam cells (Figure 13 B). In WT 
mice the expression of F4/80 was absent (Figure 14 A). On the other hand this 
immunostaining in EKO/A-IKO mice was well visible, particularly in the reticular 
dermis where foam cells accumulated, suggesting their macrophagic origin (Figure 
14 B).  
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Figure 13. Skin IHC CD3. CD3 immunohistochemical and semi-quantitative analysis. 
(A and B). Representative photomicrographs of mouse skin paraffin sections after 
anti-CD3 immunostaining. (A): C57BL/6 mice; (B): EKO/A-IKO mice. Arrows indicate 
CD3 positive cells. (C):Semi-quantitative evaluation of CD3 staining. Bars: 60 μm. 
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Figure 14. F4/80 immunohistochemical analysis. Representative photomicrographs 
of mouse skin paraffin sections after anti-F4/80 immunostaining. (A): WT mice; (B): 
EKO/A-IKO mice. Bars:30 μm. 
 
Morphometric analysis demonstrated that both epidermis and hypodermis areas 
were comparable in all the considered groups. Hypodermis thickness was 
comparable in all groups, and the hypodermis/epidermis area ratio in EKO/A-IKO and 
WT mice were not different (3.02±0.14 vs. 3.44±0.21, respectively; p>0.05). 
Accordingly with light microscopy observations on haematoxylin/eosin and semithin 
sections, showing a thickened dermis in EKO/A-IKO mice, the dermis/epidermis area 
ration in this mouse line was much higher compared to all the other mouse lines 
(36.21±3.71 in EKO/A-IKO; 16.45±6.25 in WT; 15.59±1.42 in EKO; 16.84±0.43 in hA-
I/EKO/A-IKO; p<0.0001). 
TEM analysis confirmed that the epidermis was well preserved and comparable 
among the different experimental groups (Figure 15). Epidermal layer count 
revealed, in all the four different group, three keratinocyte layers. The basal 
membrane was always continuous and no detachments between the epidermis and 
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the underlying dermis occurred. In EKO/A-IKO animals, immediately below the 
keratinocyte basal layer, large cholesterol clefts were present and arranged parallel 
to the epidermal surface (Figure 15).  
 
 
Figure 15. Transmission electron microscopy analysis of epidermis and papillary 
dermis. Representative photomicrographs of murine skin araldite ultrathin sections. 
(A): WT mice; (B): EKO mice; (C): hA-I/EKO/A-IKO mice; (D): EKO/A-IKO mice. In (D) 
arrows indicate cholesterol clefts. Bars: 2 μm. 
 
Interestingly, in the reticular dermis, where foam cells accumulated (Figure 16 A-B), 
intracellular cholesterol clefts were found inside these cells (Figure 16 C). Herein, 
these sharp and elongated structures were very much smaller than those located in 
the extracellular matrix of the papillary dermis when observed at the same 
magnification. 
Foam cells did not show any contractile fibrils inside their cytoplasm, thus suggesting 
their macrophagic origin (Figure 16). Moreover, consistent with CD3 
immunostaining, T lymphocytes were identified in the reticular dermis where foam 
cells accumulated (Figure 16 D), supporting the occurrence of a possible 
inflammatory response. 
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Figure 16. Transmission electron microscopy analysis of reticular dermis in EKO/A-
IKO mice.  Representative photomicrographs of skin araldite ultrathin sections. (A): 
extracellular cholesterol clefts; (B): foam cells; (C): intracellular cholesterol clefts; 
(D): a foam cell and a lymphocyte. In (C) arrow indicates cholesterol clefts. Bars: (A 
and C): 500nm; (B): 2 μm; (D):1 μm. 
 
Secondary lymphoid organs phenotype and histology 
Among the athero-protective effects displayed by apoA-I/HDL, a growing importance 
is attributed to its immunomodulatory role. To this aim, a macroscopic and 
histological characterization of different lymph nodes and spleen has been 
performed in all the mouse lines.  
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Figure 17. Figure 19. Weight of axillary and inguinal lymph nodes and spleens in all 
experimental groups after 22 weeks on regular chow diet. 
 
EKO/A-IKO mice were characterized by a significantly higher weight of both axillary 
and inguinal lymph nodes compared with the other mouse lines (Fig. Panel lymphoid 
organs). On the contrary, the weight of the spleen from EKO/A-IKO mice was 
comparable with those from hA-I/EKO/A-IKO mice and WT mice, whereas a 
significant increase in spleen weight was observed in EKO mice (Figure 17. Panel 
lymphoid organs). 
Histological analyses revealed that EKO/A-IKO mice had a dramatic increase in the 
amount of macrophages and granulocytes within the lymph node parenchyma in 
comparison with all the other genotypes (Fig. EKO/A-IKO detail). Moreover, three 
main features were observed specifically in EKO/A-IKO mice: i) large macrophages, 
often characterized by a foamy cytoplasm, were seen as single cell or in small group 
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in the cortex, surrounded by lymphoid cells (Fig. EKO/A-IKO detail) presence of 
granulomatous reactions in the inner cortex and the medulla, localized around a 
large number of multinucleated macrophages and cholesterol crystals (Fig. EKO/A-
IKO detail); iii) dilation of subcapsular, cortico-medullary and medullary sinuses 
(Figure 18). 
 
 
Figure 18. Histological representation of lymph nodes of EKO/A-IKO mouse stained 
with hematoxylin & eosin. Large foamy macrophages (A); granulomatous reaction 
centered around elongated empty spaces reminiscent of cholesterol crystals (B); 
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dilatation of sinuses presence of multinucleated foamy macrophages within the 
lumen of sinuses (C). 
 
In addition, neutral lipid-specific staining with Oil-Red-O indicated that WT mice had 
the lowest lipid deposition, measured as % of surface positive to O.R.O. staining 
(axillary lymph node: 0.8±0.33 %; inguinal lymph node: 1.28±0.3 %); EKO and hA-
I/EKO/A-IKO had a comparable lipid deposition (axillary lymph node: 1.35±0.63 % 
and 2.28±0.88 %, respectively; inguinal lymph node: 1.63±0.58 % and 3.22±1.67 %, 
respectively); whereas EKO/A-IKO mice had significantly increased lipid deposits 
compared with all the other genotypes (axillary lymph node: 12.17 ± 5.53 %; inguinal 
lymph node: 14.29 ± 7.69 %) (Figure 19). 
 
Figure 19. Histological representation of lymph nodes of all experimental group 
stained by Oil Red O. 
 
Both spleen histology and splenic lipid deposition resulted unaffected by 
genotype (Figure 20). 
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Figure 20. Histological representation of spleen of all genotypes. (A): WT mice; (B): 
EKO mice; (C): hA-I/EKO/A-IKO mice; (D): EKO/A-IKO mice. 
 
Leukocytes subsets 
 he anal sis of CD     cell su sets (  na ve, T central memory cells    e ector 
memor  cells) revealed that  in  eri heral  lood and s leen  E    -    mice had a 
signi cantl  increased  ercentage of   e ector memor  cells and a signi cantl  
reduced  ercentage of   na ve com ared with the other genot  es (Figure 21). 
Concomitantly, WT mice had the highest percentage of T naïve compared with all 
the other genotypes (Figure 21). In the axillary lymph node, EKO/A-IKO mice had a 
significantly increased percentage of T effector memory cells compared with the 
other genot  es and a signi cantl  reduced  ercentage of   na ve, compared with 
WT mice (Figure 21). Interestingly, in the inguinal lymph node of EKO/A-IKO mice, 
only a tendency toward an increased percentage T effector memory cells was 
detected (Figure 21). The percentage of T central memory cells resulted always 
unaffected by genotype (Figure 21).  
Moreover, the relative abundance of monocyte subsets (inflammatory vs. patrolling) 
in peripheral blood (Figure 22), as well as the percentage of 
monocytoid/plasmacytoid dendritic cells (Figure 23) and B1a/B1b lymphocytes in 
secondary lymphoid organs was unaffected by genotype (Figure 24). 
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Figure 21.  Percentage of CD4+ T lymphocytes in blood and lymphoid organs. 
 
 
 
 
Figure 22. Percentage of monocytes. 
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Figure 23. Percentage of dendritic cells in lymphoid organs. 
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Figure 24. Percentage of B lymphocytes in lymphoid organs. 
 
Secondary lymphoid organs transcriptomics 
PolyA+ RNA recovered from axillary/inguinal lymph nodes and spleen of EKO/A-IKO 
and hA-I/EKO/A-IKO mice (representing the two extremes of apoA-I concentration) 
was subjected to sequencing on an Illumina HiSeq2000 instrument (3 biological 
replicates for each experimental condition). An average of 21 x 106 reads was 
produced by each sequencing reaction for each biological replicate, virtually all the 
reads passed the QF, of these, between 95% and 99% mapped consistently to the 
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reference transcriptome. Direct comparisons between the transcriptomes of the two 
different genotypes were performed. 
In total, 784 genes were identified as differentially expressed (DE) in the axillary 
lymph node and 514 in the inguinal lymph node after comparing the two genotypes. 
Of them, 365 genes resulted DE in both lymph nodes (279 upregulated in EKO/A-IKO 
vs. hA-I/EKO/A-IKO mice and 86 downregulated in EKO/A-IKO vs. hA-I/EKO/A-IKO 
mice).  
 
To better understand the biological significance of the data gathered from the 
transcriptome analysis, the Gene Ontology (GO) approach was used to perform an 
enrichment analysis on the gene sets.  GO terms (GOterm Biological Process) 
upregulated in both axillary and inguinal lymph nodes of EKO/A-IKO vs. hA-I/EKO/A-
IKO mice were related to immune response, response to wounding, inflammatory 
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response, chemotaxis, positive regulation of endocytosis, phagocytosis and 
proteolysis. Upregulated genes were mainly involved in lysosomal degradation 
(Cd63, Cd68, Ctsg, Ctsk, Ctsl, Ctss, Lipa, Slc11a1), cytokine-cytokine receptor 
interaction (Ccl3, Ccl6, Ccl9, Ccr1, Ccr5), cell adhesion (Cd276, Cadm1, H2-M2, 
Itgb2l), hematopoiesis (CD9, CD14), innate and adaptive immune response (Mpo, 
Clec7a, Fcer1g, Fcgr1, Fcgr3, Aicda, C1qc, C1qa C1qb, Il18bp, Prdx1, Tlr8, Tlr13), and 
metalloprotease activity (Mmp3, Mmp8, Mmp12, Mmp13, Mmp14, Mmp19). 
GOterms downregulated in both lymph nodes of EKO/A-IKO vs. hA-I/EKO/A-IKO mice 
were involved in fatty acid metabolism and oxidation/reduction. 
In the spleen, the comparison of the transcriptomes obtained from EKO/A-IKO and 
hA-I/EKO/A-IKO mice showed substantially no differences with only six DE genes, 
downregulated in EKO/A-IKO mice (Apol11b, Cyr61, Dnaja1, Dnajb1, Hspa1a, 
Hspa1b, Hsph1). 
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DISCUSSION 
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Several studies have clearly established that HDL cholesterol levels are inversely associated with 
the incident of cardiovascular events (Gordon et al 1989). The major protective role exerted by 
HDLs is related to reverse cholesterol transport (RCT), a process that removes cholesterol from 
peripheral cells, including the vessel walls, and delivers it to the liver for excretion into the biliary 
system (Rosenson et al 2012). On the other hand, VLDL and LDL particles transport and deliver 
cholesterol to peripheral tissues, such as arteries, carrying out an atherogenic action. Recent 
studies have demonstrated that the HDL-induced athero-protection is also mediated by anti-
oxidant, anti-apoptotic, anti-inflammatory and anti-thrombotic effects. The use of animal models 
has increased our understanding of atherosclerosis. Mouse represents the most frequently used 
species for study atherosclerotic process (Getz et al 2012). In particular, the EKO mouse is the 
most widely used model of atherosclerosis, characterized by the deletion of gene coding for the 
expression of apoE, the apolipoprotein which plays an important roles in lipoprotein metabolism. 
These mice, maintained at chow diet (low fat, no cholesterol) exhibit a strong 
hypercholesterolemia, condition associated with atherosclerosis development at the aortic sinus 
(Imazuimi et al 2011). Conversely, the murine model A-IKO, characterized by the deletion of apoA-
I, the main protein component of HDL, shows a significant reduction of total cholesterol and 
plasma HDL, but this effect is not associated with an increase of atherosclerosis susceptibility (Li et 
al 1999).  
The aim of the present project was to evaluate the effects of HDLs on atherosclerosis 
development, phenotype, inflammation and immune function through the use of genetically 
modified mice deprived of, or overexpressing, apoA-I, in the apoEKO background.  
The first effect of the apoA-I deficiency was on plasma cholesterol levels and its distribution 
among lipoproteins. An increase would be expected in VLDL and LDL due to the deletion of apoE 
together with an almost total absence of HDLs, caused by the deletion of apoA-I. The results of the 
enzymatic assay for total cholesterol, both on plasma and lipoprotein fractions obtained by FPLC, 
have partially confirmed this expectation. EKO/A-IKO mice showed an increase in VLDL/LDL 
cholesterol and a severe decrease of HDL cholesterol. However, the cholesterolemia in EKO/A-IKO 
animals was comparable with that measured in C57BL/6 mice and was 3-fold lower than the 
concentration observed in EKO and hA-I/EKO/A-IKO mice. This latter mouse model, is 
characterized by a large HDL cholesterol peak and by a marked presence of VLDL-LDL particles, 
although less prominent than in EKO animals.  
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Despite a dramatic reduction in HDL levels, A-IKO mice did not show an increase in susceptibility to 
atherosclerosis development. The lack of atherosclerosis lesions in apoA-I deficient mice could be 
explained by the presence in this model of considerable amounts of apoE, which may functionally 
compensate, at least in part, for the apoA-I deficiency. Based on this experimental evidence and 
on the modest increase in circulating VLDLs and LDLs observed in EKO/A-IKO mice, no marked 
development of atherosclerotic lesions was expected in this model. En-face analysis of the aorta 
detected a comparable number of atherosclerotic plaques between EKO/A-IKO and EKO animals. 
Conversely, an unexpected result was instead obtained through histological evaluation with 
hematossylin&eosin and Oil Red O staining of the cardiac district. Surprisingly, EKO/A-IKO mice not 
only developed atherosclerotic plaques at the aortic sinus, with a wider extension than the EKO 
animals, but also showed atherosclerotic lesions in the common coronary arteries. Previous 
studies performed on mice lacking both LDLR and apoA-I, fed high fat diet, displayed an 
atherosclerosis development at the aortic sinus with the same extent compared to single knockout 
LDLR mice (Zalabawi et al 2003). Standard murine models of atherosclerosis did not develop 
lesions in coronary artery. But genetic combination, obtained by crossing different knockout 
model, can lead to atherosclerotic plaques in coronary arteries. Mice deficient in both apoE and 
LDLR, fed atherogenic diet for 7 month, showed atherosclerosis in this district (Caligiuri et al 1999). 
The murine model EKO/SR-BIKO displayed coronary arterial lesion and premature death at 5 week 
of age (Braun et al 2002). The molecular mechanisms responsible for the larger extension of 
atherosclerotic plaques at the aortic sinus and the presence of atherosclerotic lesions in the 
common coronary arteries in EKO/A-IKO mice, may be due to an altered cholesterol flux into or 
out of the artery wall, and a decreased RCT. Both apoA-I and apoE play a central role in lipoprotein 
metabolism and can protect mice from atherosclerosis. ApoE influences atherosclerosis 
stimulating reverse cholesterol transport and activating enzymes involved in lipoprotein 
metabolism such as hepatic lipase HL, CETP and LCAT. This apolipoprotein also shows an important 
role in the clearance of atherogenic lipoproteins, in its absence cholesterol and triglyceride-rich 
lipoproteins accumulate in the blood resulting in increased of deposition in the vasculature 
(Mahley 1988). In addition, apoE exerts local effects of the artery, facilitating the efflux of 
cholesterol from the macrophages. Apo-I is directly involved in RCT preventing the accumulation 
of lipid in the vessel walls of arteries, mediating cholesterol efflux from cells and participating in  
clearance of lipoproteins from plasma. Our results suggest that EKO/A-IKO mice could be 
considered an innovative murine model of occlusive coronary artery disease useful to investigate 
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the mechanisms underlying the development of atherosclerosis and to study the role of 
endogenous factors or the effects of pharmacological therapies on coronary atherosclerosis.        
Conversely, in hA-I/EKO/A-IKO animals, murine line characterized by high level of apoA-I, no 
atherosclerosis was observed in any of the segments of aorta and in the cardiac district. Therefore, 
these results support the concept that HDL apoA-I is highly protective against atherosclerosis. 
Previous studies have showed a direct antiatherogenic role for apoA-I, demonstrating that high 
level of apoA-I and HDL dramatically reduce atherogenesis (Badimon et al 1990) (Pàszty et al 
1994). 
In addition to atherosclerosis development, we observed in EKO/A-IKO mouse an interesting 
cutaneous phenotype. In particular, this mouse model was characterized by deep alterations in 
the skin structure, with a massive dermal accumulation of cholesterol clefts, foam cells and T 
lymphocytes. Conversely, hA-I/EKO/A-IKO mice displayed a normal phenotype comparable with 
that of EKO and C57Bl/6 animals. Modifications of skin morphology have been reported in other 
genetically modified mouse models, all characterized by a severe, genetically- and/or dietary-
induced, hypercholesterolemia. Particularly, skin abnormalities have been observed in 
hypercholesterolemic EKO mice and low-density lipoprotein receptor (LDLr) KO mice crossed with 
mice deficient in acyl-CoA acyltransferase-1 (ACAT1), the enzyme that catalyzes intracellular 
cholesterol esterification (Accad et al 2000). These mice showed hair loss, xanthomatosis, and 
marked thickening of the dermis with diffuse extracellular cholesterol crystals, accompanied by a 
severe inflammatory cell infiltrate. Severe xanthomatosis and foam cell accumulation was also 
observed in EKO mice with macrophage inactivation of ABCA1 (Aiello et al 2002); Finally, in 
hypercholesterolemic LDLRKO mice fed a high-fat/high-cholesterol diet, apoA-I deletion led to 
massive cholesterol accumulation in skin, accompanied by an increase in dermal thickness, hair 
loss and macrophage infiltration (Zabalawi et al 2007)(Wilhelm et al 2010). The present study 
shows that hyperlipidemia is not an essential requirement for the development of skin 
abnormalities, but that HDL deficiency itself can drive a massive dermal lipid deposition in mice, in 
the presence of normal plasma cholesterol levels. Xanthomas arising from this specific 
dyslipidemic condition have been poorly analyzed in humans. One case report, showing the 
histological features of xanthomas arising from an HDL deficiency status, documented the 
presence of T lymphocytes, as well as of clusters of foam cells with free and esterified cholesterol 
accumulation (Lindeskog et al 1972). These features resemble those found in our study in EKO/A-
IKO mice, thus suggesting that this genetically modified mouse line could represent a valid animal 
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model for the study of this pathological skin condition. The deletion of both apoA-I and apoE led to 
the formation of macrophage-derived foam cells able to accumulate esterified cholesterol in their 
cytoplasm. Since in this mouse model cholesterol efflux is impaired, toxic free cholesterol possibly 
accumulates causing cell death and, as a consequence, dermal deposition of cholesterol clefts 
which possibly results in an inflammatory condition. This model reproduces for the first time the 
cutaneous phenotype of human apoA-I deficiency, characterized by xanthomatous deposition in 
the absence of a hyperlipidemic status. This experimental model will thus represent a useful tool 
for investigating, through time course studies, the onset and mechanisms involved in the 
development of this cutaneous pathological condition.  
The present work also demonstrated that the deficiency of apoA-I in apoEKO background lead to 
an enlargement of skin draining lymph nodes characterized by foamy macrophages accumulation 
and cholesterol deposition, predisposing to granulomatous reactions. Previous studies on mice 
lacking LDLR and apoA-I genes, displayed enlargement and inflammation in the lymph nodes in 
response to an atherogenic diet (Wilhelm et al 2009). In contrast, hA-I/EKO/A-IKO and EKO mice 
did not show an increase in lymph nodes size or cellularity. These results suggest that plasma 
apoA-I prevents lymph node enlargement, lipid accumulation and peripheral lymphocytes 
proliferation. Cholesterol accumulation in skin draining lymph nodes could be explained by the 
impaired cholesterol efflux. The combined analysis of lymph nodes transcriptome revealed that 
apoA-I deficincy in apoEKO background cause a widespread induction of gene related to innate 
and adaptive immune responses, particularly those associated to lysosomal activity in phagocytes 
as well as to T-lymphocyte and B-lymphocyte activation.  
In parallel we also characterized mouse leukocytes by flow cytometry. In peripheral blood and 
lymphoid organs EKO/A-IKO mice displayed a significant increase in the percentage of CD4+ T 
effector memory lymphocytes compared to the other murine lines. This subset of CD4+ is strongly 
associated with atherosclerosis supporting the relevance of adaptive response in cardiovascular 
disease (Lahoute et al 2011). Lymph nodes immune cells are involved in atherosclerosis from the 
formation of foam cells to the migration of dentritic cells from atherosclerotic lesions to lymph 
nodes. CD4+ effector memory cells are supposed to migrate into atherosclerotic plaques where 
they sustain the inflammatory response (Ammirati et al 2012). Thus, the marked atherosclerosis in 
EKO/A-IKO mice could also be explained, at least in part, by a modulation of the inflammatory 
response mediated by CD4+ T lymphocytes. Interestingly, the presence of plasma apoA-I increased 
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T       cells and decrease T effector memory cells suggesting that this apolipoprotein can control 
T cell homeostasis in peripheral blood and lymph nodes by regulating the T naive/T effector  
balance.  
In conclusion, the present study demonstrated that apoA-I deficiency in apoEKO background 
brings about severe atherosclerosis at the aortic sinus. Surprisingly, this model show 
atherosclerotic plaques also at common coronary arteries, thus may prove to be a useful model to 
investigate the mechanisms underlying the development of coronary disease. The experiments 
described in the present work helped in clarifying the role of apoA-I in inflammation. The deletion 
of apoA-I in athero-prone murine line lead to cholesterol accumulation and inflammation in skin 
and skin draining lymph nodes. These results are also associated with  activation and increase in 
CD4+ T effector memory lymphocytes in peripheral blood and lymphoid organs. These effects 
were obtained, for the first time, with low plasma cholesterol levels and without dietary challenge, 
but only with genotype influence. Taken together our results suggest a strong association between 
plasma apoA-I, cholesterol metabolism, atherosclerosis, inflammation and autoimmunity. 
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